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 The treatment of intracellular pathogens can be difficult as many otherwise 
efficacious antibiotics could be rendered less effective or even completely ineffective due 
to the inability to pass through the barrier of the cell membrane to gain access to the 
bacteria. In this study, a number of antibiotics were tested in order to determine their 
effectiveness in killing intracellular Burkholderia pseudomallei or Salmonella 
Typhimurium. To this end, an in vitro intracellular model using a murine macrophage 
cell line, J774.1, was conceived. In order to eliminate the extracellular bacteria while 
protecting the intracellular population, kanamycin or gentamicin were used. These 
antibiotics were rapidly bactericidal while penetrating cells poorly.  
A number of antibiotics were tested against intracellular B.pseudomallei; 
amoxicillin-clavulanate, ciprofloxacin, ceftriaxone, chloramphenicol, clarithromycin, 
erythromycin, piperacillin, piperacillin-tazobactam, rifampicin, tetracycline and 
doxycycline. Among these, ciprofloxacin, amoxicillin-clavulanate and piperacillin-
tazobactam showed the most promise while ceftazidime and meropenem, while showing 
relatively poorer intracellular penetration, could still be useful as therapy against 
intracellular B.pseudomallei. Due to the changes in biosafety regulations, further work on 
B.pseudomallei could not be carried on.  
 Against intracellular S.Typhimurium, the most effective antibiotics among those 
tested were ciprofloxacin and rifampicin. Cefotaxime and ceftriaxone showed reduced 
activity against intracellular salmonellae while both tetracycline and chloramphenicol 
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were at best bacteriostatic except at very high concentrations. Meropenem was the least 
effective against intracellular S.Typhimurium. Antibiotics combinations were also tested 
and only the combination of tetracycline and chloramphenicol showed some synergism. 
Antagonism was recorded when either tetracycline or chloramphenicol was used in 
combination with ceftriaxone.  
 In general, it was shown that antibiotics demonstrated varying capabilities in 
killing intracellular bacteria, with most showing a marked decline in activity compared to 
their action against extracellular bacteria. 
 It was also shown that activation of the J774.1 cells by pre-incubating with 
interferon-gamma also primed the cells to kill the infecting salmonellae. However, no 
synergistic activity was observed when cells primed by IFN-γ were infected and treated 
with the test antibiotics. Antagonistic activity was observed when the IFN-γ primed cells 
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 2.1 Melioidosis 
 Melioidosis is a disease that primarily occurs in the tropical regions between 20ºN 
and 20ºS of the equator and is found to be particularly endemic to South-east Asia and 
also to northern regions of Australia. In Thailand, particularly in the north-eastern 
portion, melioidosis has accounted for 20% of all community-acquired septicaemia for 
the past 20 years (Chaowagul et al, 1989). 
 The causal organism of melioidosis is Burkholderia pseudomallei. This soil 
bacterium has been shown to be highly resistant to many antibiotics. The bacterium is 
also facultatively intracellular and is able to survive within macrophages (Egan et al, 
1996). It is able to remain dormant within the host macrophages and persist within the 
infected host for months or even years, a potential “time-bomb” which can erupt when 
the conditions are right. This means that even a patient who has apparently been cured 
can suffer a relapse of the disease many months or years later. Infected individuals who 
have been asymptomatic can also suffer from the disease many years post-infection if the 
individual develops an illness which predisposes to late reactivation. Such predisposing 
factors include diabetes (the primary risk factor) as well as others including hypertension, 
kidney or heart disease or immunodeficiency. This disease was referred to as the 
“Vietnamese time-bomb” by the American veterans of the war. Approximately 1-2% of 
healthy soldiers and as many as 9% of wounded soldiers who had served during the war 
in Vietnam were serologically positive and a significant number of these had latent 
infections, which recrudesced after many months or even years (Sanford et al, 1995). The  
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ability of B.pseudomallei to persist within the host cells may protect the bacteria from the 
effect of antibiotic therapy directed against it. The ability of antibiotics to penetrate 
eukaryotic cells varies according to the class and example of the drug itself. In some 
cases, antibiotics that have been shown to be efficacious against the extracellular bacteria 
in vitro could be rendered ineffective by the persistence of the bacteria within the host 
cell due to the poor intracellular penetration of the drug.  
 As mentioned previously, B.pseudomallei is highly resistant to many antibiotics in 
vitro and this included antibiotics from the classes of aminoglycosides (the exception 
being kanamycin), early penicillins, first- and second-generation cephalosporins, 
polymixins and macrolides. However, some antibiotics have been shown to be clinically 
efficacious including ceftazidime, imipenem, amoxicillin-clavulanate, trimethoprim-
sulfamethoxazole, doxycycline and chloramphenicol. Earlier therapy had involved the 
use of various combinations of chloramphenicol, doxycycline and trimethoprim-
sulfamethoxazole. However, the overall success rate of treatment using these drugs was 
poor, with a mortality rate of 82-87% in patients suffering from acute melioidosis 
(Leelarasamee, 1998). The introduction of ceftazidime cut the mortality rate by half and 
the rate was further reduced with new drug treatment regimes, including a combined 
regime with intravenous infusions of ceftazidime or imipenem or amoxicillin-clavulanic 
acid. However, treatment for melioidosis remained an arduous process involving weeks 
to months of parenteral antibiotics therapy followed by months of oral maintenance 
therapy. Yet, as can be observed from the local statistics from 2003, the fatality rate was 
still an unacceptably high 11.9% in Singapore. And to further complicate matters, even  
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these intensive antibiotics treatment regimes could not completely eliminate the risk of 
recrudescence (Chaowagul et al, 1993).  
 As such, there exists a need to reconsider the choice of antibiotics used to treat 
melioidosis. In addition to the need of finding new, more effective antibiotics that are 
able to clear the infection with greater success, it would also be useful to re-evaluate our 
arsenal of antibiotics in order to determine their efficacy against intracellular 
B.pseudomallei. This is important as the aim of melioidosis therapy includes not only the 
control of the acute infection but also the elimination of the latent intracellular bacteria 
which can remain in the patient and cause recrudescence in the future. 
 In this project, it was our intention to evaluate certain of the antibiotics commonly 
prescribed for the treatment of melioidosis and determine their ability to eliminate 
intracellular B .pseudomallei using an in vitro model. Also, other antibiotics were also 
tested to determine their effectiveness in killing the bacteria, both within the host cell as 
well as without. In our model, a murine macrophage cell line (J774.1) was used as host 
cells for the bacteria. These cells were infected with B.pseudomallei and then subjected to 
the test antibiotics. The efficacy of the antibiotics in eliminating the intracellular bacteria 
was then determined by viable counts in predetermined time points. Antibiotic 
combinations were also tested for possible synergistic or antagonistic effects. 
 In animal models of melioidosis, interferon-gamma (IFN-γ) has been shown to 
play a crucial role in host defence (Santanirand et al, 1999). Patients with septicaemic 
melioidosis also showed a very vigorous pro-inflammatory cytokine response, with levels 
of IFN-γ, tumour necrosis factor (TNF), interleukin-6 and interleukin 8, interleukin-10  
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and interleukin-18 all found to be raised (Brown et al, 1991; Suputtamongkol et al, 1992 
; Friedland et al, 1992 and Simpson et al, 2000). It was demonstrated that J774.1 cells 
stimulated with IFN-γ showed a strong dose-dependent inhibition of intracellular growth 
of B.pseudomallei (Miyagi et al, 1997). Therefore, it is of interest to investigate whether 
there is any synergistic or antagonistic effect when IFN-γ is used in combination with any 
of the test antibiotics. 
 AT the beginning of the project, we worked in collaboration with A/P Yap Eu 
Hian (Department of Microbiology, NUS) and his research team, who had been working 
with B.pseudomallei for many years, and followed his laboratory’s safety practices. In 
particular, all fluid handling and dispensing was carried out within a Class II biosafety 
cabinet, and incubations were carried out in a dedicated incubator reserved for work 
involving B.pseudomallei. During the course of the project, a general university-wide 
reassessment of safety procedures meant that B.pseudomallei, being classified as a 
Category 3 pathogen, could only be handled in a full Containment Level 3 laboratory, 
and since the department of Microbiology lacks such a facility, we could not continue 
work on this organism. 
  
 2.2 Salmonella Typhimurium 
 Salmonella Typhimurium (correctly, Salmonella enterica subspecies enterica 
serotype Typhimurium), is a major food-borne pathogen found throughout the world. In 
Singapore, periodic outbreaks of salmonellosis caused by multi-resistant salmonella 
strains have been recorded; S.Typhimurium was endemic in 1971-1997, S.orainberg in  
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1978-1979 and S.blockley in 1983 (Epidemiological News Bulletin, March 2001). In 
1999, the dominant serotypes of salmonellae found in Singapore were S.Enteritidis 
(20.3%), S. Stanley (12.8%), S.Weltevreden (10.8%) and S.Typhimurium (7.3%).  
  In July 2000, an outbreak of S.Typhimurium DT104L was reported. The strain 
was demonstrated to be resistant to ampicillin, chloramphenicol, gentamicin, 
streptomycin, tetracycline and sulphonamide (Resistance or R-type ACGSTS3). 
Altogether, a total of 33 isolates of S.Typhimurium of the same phage type (DT104L) and 
R-type ACGSTS3 were identified. 17 of the patients were hospitalised and 2 were treated 
as outpatients. No mortality was reported (Epidemiological News Bulletin, March 2001). 
 Although usually a self limiting disease in humans, some patients with 
S.Typhimurium infections do suffer from more severe illness or fail to recover, especially 
those at the extremes of life and immuno-compromised patients. It was also reported that 
some multi-resistant strains like DT104 were observed to cause more serious infections 
with higher rate of hospitalisation and mortality (Wall et al,1994). S.Typhimurium is also 
a serious complication in HIV-positive individual and has been implicated as a major 
causal organism of bacteraemia and gastrointestinal infections. In these cases, 
antimicrobial therapy is indicated. The key antimicrobial drugs used in the treatment of 
Salmonella Typhimurium infections are presently ciprofloxacin or azithromycin. 
Ceftriaxone and cefotaxime are also usually active.  
  Salmonellas are able to enter and persist within phagocytic cells including 
macrophages. As the effectiveness of an antibiotic against an intracellular organism is 
also dependent on the permeability of the host cell to the antibiotic, an antibiotic that is  
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effective against extracellular salmonellae could potentially be rendered ineffective 
against bacteria sequestered within the eukaryotic host cells (Hand et al, 1986). As such, 
it would be of interest to determine the ability of certain antibiotics to eliminate the 
intracellular salmonellae. This would be of interest not only against S.Typhimurium 
infections but potentially S.Typhi infections as well since similar drugs are used also for 
therapy in typhoid fever and S.Typhimurium is a reasonable intracellular model for 
similar S.Typhi infections.  
A drug that is efficacious against intracellular salmonella would likely be useful 
to ensure the complete clearance of the pathogen and reduce the risk of carrier status in 
patients. 
 As with B.pseudomallei, murine macrophage cell line, J774.1, were used as host 
cells for S.Typhimurium and various antibiotics and antibiotic combinations were tested 
for their efficaciousness against intracellular S.Typhimurium. IFN-γ was also introduced 
to determine if stimulation by this cytokine had any effect on the ability of 
S.Typhimurium to persist within the macrophages, and its potential for synergy with 
antibiotics was also investigated. In addition, we had managed to procure a human 
monocytic cell line, THP-1 and repeated the S.Typhimurium intracellular antibiotics 
killing assays with the antibiotics used in the assays using the murine J774.1 cells. This 
was in order to determine the difference in efficacy, if any, when the same antibiotic was 
used against either cell line. This would provide a good estimate regarding how well the 
observations made with the J774.1 cells would be applicable against S.Typhimurium in 
human monocyte-derived macrophages. 
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3. A SURVEY OF LITERATURE 
 
3.1 Burkholderia pseudomallei 
 
 3.1.1 History 
 In 1911, Captain Alfred Whitmore and C S Krishnaswami, of the Rangoon 
General Hospital, recorded the discovery of a “hitherto undescribed glanders-like 
disease”(White, 2003). Glanders is an abscess-forming infection caused by the organism 
Burkholderia mallei, common in horses and occasionally affecting humans.  Whitmore 
and Krishnaswami managed to isolate the causal bacterium and proposed the name 
Bacillus pseudomallei. In the ensuing years, numerous cases were reported in humans 
and animals. In 1932, Stanton and Fletcher had documented sufficient cases in both man 
and animals to publish a definitive monograph on the disease caused by B. pseudomallei, 
by then termed melioidosis (Stanton and Fletcher, 1932). 
 Over years, the name of this bacillus discovered by Whitmore and Krishnaswami 
has undergone several name changes. In the later half of the 20th century, it was known as 
Pseudomonas pseudomallei. In 1992, it was reassigned to the newly created genus, 
Burkholderia and henceforth known as Burkholderia pseudomallei (Yabuuchi et al, 
1992). Also in this genus are the closely related species, B. mallei and B. cepacia. In 
addition, some low virulence or avirulent strains, dubbed B.pseudomallei-like strains 
were isolated and it was later shown that these strains showed significant differences in 
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the 16S rRNA sequences and in fact were different but closely related species (Brett et al, 
1997), an example of which was B.thailandensis. 
 
 3.1.2 Characteristics 
 B. pseudomallei is a motile, aerobic, non spore-forming, Gram negative 
bacterium. It is oxidase positive and utilizes glucose in an oxidative manner.  It can be 
grown aerobically on most agar media. A selective medium commonly used in the 
isolation of B. pseudomallei is Ashdown's media (Ashdown, 1979). The colonies develop 
a characteristic appearance called rugose, or resembling corn-flower heads, and they take 
up the crystal violet dye present in the media. A typical “soil” smell can also be detected, 
although some workers warn against sniffing such bacterial cultures. 
 
 3.1.3 General epidemiology 
 The disease caused by B. pseudomallei, melioidosis, occurs primarily in the 
tropical belt between the latitudes of 20ºN and 20ºS of the equator. Melioidosis is 
endemic to the Southeast Asia region and northern Australia. It is particularly common in 
Thailand, especially the north-eastern portion (Nachiangmai et al, 1985; Charoenwong et 
al, 1992). It is also endemic in Malaysia, Indochina, Myanmar, the Philippines, Hong 
Kong, Taiwan and certain provinces in mainland China as well as Singapore. In addition, 
sporadic incidents were also reported from the Indian subcontinent, Central and South 
America, the Middle East and Guam. The disease is rare in the Western hemisphere and 
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virtually all reported cases were travellers who had resided in the endemic countries or 
immigrants from these countries. 
 The bacterium is a free-living soil saprophyte and can be found most commonly 
in surface water and soil after rain fall (Thin et al, 1971) and infections are most 
frequently encountered at the beginning or immediately after the wet season (Thomas et 
al, 1979). It is common in still, rather than flowing water and hence can frequently be  
isolated from rice paddy fields or puddles of water formed after rain (Strauss et al, 1967). 
It can also survive in underground soil 20-45cm deep, if the area is under shade (Thomas 
et al, 1979). 
 In northeast Thailand, the bacterium can be readily isolated from more than 50% 
of its paddy fields (Wuthiekanun et al, 1995). In southern Thailand, the bacterium was 
found in 60.9% of soil and water samples from rubber plantations and 78.1% of bottom 
sediments of rice fields (Nachiangmai et al, 1985). In west Malaysia, it was reported that 
B. pseudomallei was found in 14.5% to 33.3% of wet rice paddy fields and fields of 
newly planted oil palms while in contrast, the isolation rate for surface waters in forested 
areas were 0.8% to 3.2% ( Strauss et al, 1969). At 1.6%, the isolation rate from 
environmental samples in Australia was considerably lower than that in Southeast Asia 
(Thomas et al, 1979).  
 The reasons for the concentration of clinical melioidosis in certain areas such as 
north-eastern Thailand are unknown. It could be due to a variety of environmental 
factors, for example, high humidity and heat, the chemical composition of the surface 
water and soil, the particularly virulence of the local strains, the nature of contact (e.g., 
 11
                                             Studies on Antibiotics Action on Intracellular Bacteria 




through extensive rice farming carried out in the region) or the susceptibility of the 
exposed population (Thomas et al, 1979; Dance, 1991). 
  
 3.1.4 Epidemiology of melioidosis in Singapore  
A sampling exercise carried out in Singapore which tested 136 surface water 
samples from forests, roadside drains and sports fields. Of these, 8 samples (5.9%) were 
tested positive (Thin et al, 1971). 
In 2003, a total of 40 cases of melioidosis were reported in Singapore compared 
to 35 in the year before. Out of the 40 cases recorded in Singapore in 2003, the case-
fatality rate was 10% while in 2002, a case-fatality rate of 6% was reported 
(Epidemiological News Bulletin, July-September 2004). The clinical characteristics and 
the presence of any predisposing medical conditions are shown in Figure 3.1.The 
majority of the cases reported were found to fall within the period of high rainfall 
between February and May (Figure 3.2). In Singapore, melioidosis had been an 
administratively notifiable disease since October 1989, that is, any case of melioidosis in 
the country must be reported to the Ministry of Health.  
A sudden spike in the number of recorded cases of melioidosis was recorded from 
January-June 2004. Altogether, 58 cases were recorded, of which 52 were confirmed as 
local in origin. Compared with 14 local cases recorded in the same period during 2003, 
this was a highly significant increase.  The overall case-fatality was reported to be 42.3%, 
with the highest case-fatality rate in those aged 55 years and above (59.1%). This 
outbreak was characterised by an unexpectedly high incidence of patients presenting with 
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the pneumonic form of the disease (73.1% compared to 36.4% in 2003) and a high case-
fatality rate of 42.3% (13.6% in 2003).  The details of this outbreak were recorded in the 
Epidemiological News Bulletin, July-September 2004. It was also postulated that this 
increase in melioidosis cases were related to the significantly higher rainfall in the 
January-June period of 2004 (a mean of 240mm monthly) compared to the same period in 
2003 (211mm). 
 
Table 3.1: Table of symptoms presented by melioidosis patients in Singapore 
during January 2002-July 2004. Also indicated at the bottom of the table was the 
presence of any common predisposing conditions for acute melioidosis. (Source: 
Epidemiological News Bulletin, July-September 2004)










Fever 25 (75) 34 (85) 51 (89) 110 (83) 
Chills 25 )75) 6 (15) 18 (32) 49 (37) 
Respiratory symptoms 
Cough 16 (46) 12 (30) 33 (58) 61 (46) 
Shortness of breath 5 (14) 5 (13) 23 (40) 33 (25) 
Gastrointestinal symptoms 
Abdominal pain 3 (9) 3 (8) 9 (16) 15 (11) 
Vomiting 2 (6) 2 (5) 6 (11) 10 (8) 
Diarrhoea 3 (9) 0 7 (12) 10 (8) 
Abscess (soft tissue/ systemic) 
Soft tissue abscess(es) 13 (37) 12 (30) 7 (12) 32 (24) 
Systemic abscess(es) 6 (17) 2 (5) 12 (21) 20 (15) 
None 16 (46) 26 (65) 38 (67) 80 (61) 
Pneumonia 14 (40) 13 (33) 40 (70) 67 (51) 
Bacteremia (blood culture 
positive) 
23 (66) 24 (60) 38 (67) 85 (64) 
One or more concurrent 
medical conditions 
19 (54) 29 (73) 51 (89) 99 (75) 
Cardiac diseases 5 (14) 4 (10) 14 (25) 23 (17) 
Hypertension 16 (46) 10 (25) 17 (30) 43 (33) 
Diabetes mellitus 13 (37) 18 (45) 40 (70) 71 (54) 
Renal diseases 6 (17) 8 (20) 17 (30) 31 (23) 
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Figure 3.1: Graph depicting the occurrence of melioidosis in Singapore 
during January 2002 to July 2004. (Source: Epidemiological News Bulletin, July-




 3.1.5 Melioidosis: The Disease 
 Melioidosis is a disease that is particularly prevalent during the rainy seasons in 
endemic regions (Chaowagul et al, 1989).  The people mainly affected are those that had 
direct contact with wet soils, for example, rice farmers and their family and workers who 
work in the fields without the benefit of protective clothing. It is believed that the rising 
water tables during the wet seasons help percolate the organism up through the 
underlying soil to the surface, therefore increasing the risk of exposure for both humans 
and animals. 
Melioidosis may be acquired through contact with water or soil which can 
contaminate an exposed wound or abrasion on the patient. Another important route of 
infection is via the inhalational route. This newer mode of infection became particularly 
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apparent during the Vietnam War, where it was observed that a disproportionate number 
of helicopter crewmen succumbed to melioidosis compared to other soldiers based within 
the same region. It was then proposed that the rotors of the helicopters stirred up the 
infectious soil particles around the landing zone and facilitated the inhalation of these 
particles by the crewmen (Howe et al, 1971).  Alternative routes of infection involving 
the ingestion of the causal organism, fomite transmission or human-to-human 
transmission had also been implicated, but to a much lesser extent (McCormick et al, 
1975). No reports of animal to human transmission had been recorded to date (Dance, 
1990). 
 Interestingly, although fulminant bacteraemic melioidosis may occur in an 
otherwise normal host, it was found that there exist certain predisposing factors that 
greatly increased the risk of the host succumbing to fulminant melioidosis.   In a study by 
Suputtamongkol et al (1999), conducted at 4 hospitals in north-eastern Thailand, it was 
reported that cases without obvious risk factors accounted for only 36% of the total 
number of patients suffering from fulminant melioidosis. 
 
 3.1.5a. Predisposing factors to melioidosis 
 A number of pathological factors have been correlated with the increased 
susceptibility of the patient to challenge by B. pseudomallei. Particularly, it had been  
found that the incidence of bacteraemic melioidosis is higher in patients with pre-existing 
diabetes mellitus. In one study conducted in a hospital in north-eastern Thailand, it was 
been shown that 32% of patients with bacteraemic melioidosis admitted into the hospital 
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during the one-year study also had histories of diabetes mellitus (Chaowagul et al, 1989). 
A study using diabetic infant rats as infection model substantiated the above hypothesis 
as these were shown to be much more susceptible to challenge with B.pseudomallei 
compared to non-diabetic infant rats (Woods et al, 1993). In fact, Suputtamongkol et al 
(1999), had concluded that diabetes mellitus was by far the most significant of the risk 
factors acute melioidosis.  
 Other known clinical risk factors for infection with B. pseudomallei include 
excessive alcohol consumption, chronic renal impairment, chronic pulmonary disease, 
various cardiac diseases, hypertension, leukaemia and lymphoma, corticosteroid therapy, 
immunodeficiency diseases and neoplasms. Interestingly, ingestion of kava (Piper 
methysticum), a plant consumed for its psychoactive substances, was recently implicated 
in Australia (Short, 2002). Perhaps paradoxically, melioidosis is not known to be 
associated with AIDS (Kanai et al, 1992) 
 
 3.1.5b. Clinical symptoms 
 Melioidosis presents as a febrile disease with protean clinical manifestation 
affecting many organs and causing a variety of illnesses. As such, the diagnosis of 
melioidosis from the symptoms is often difficult and suspected cases must be confirmed 
by the isolation of B. pseudomallei from patient samples or via serological methods.  
 A classification scheme for melioidosis had been advanced by Howe et al (1971) 
which divided the cases into acute, sub-acute and chronic melioidosis.   
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 The acute form of the disease is divided into 2 forms, the acute pulmonary and the 
acute septicaemic form. The acute pulmonary form develops rapidly and is characterized 
by high fever and pulmonary distress followed by the development of visceral abscess. If 
untreated, death follows within a few days. The acute septicaemic form is also rapidly 
fatal if untreated and presents a number of symptoms including malaise, meningitis, 
cellulitis and also cutaneous and subcutaneous lesions.  
 Sub-acute melioidosis is probably best characterised as a prolonged febrile illness. 
Multiple abscess formation can be observed and the organism is readily culturable from 
blood, urine, pus and other tissues or secretion in the later stages of infection. In many 
untreated cases, death can occur within weeks or months. 
 The chronic form of melioidosis, also called the sub-clinical form, is the most 
common manifestation of the disease. It is usual that this manifestation remained 
undiagnosed in the infected individual until it was activated by a traumatic event such as 
a depression in the immune system or upon the post-mortem examination of tissues. Most 
individuals that were exposed to environmental B. pseudomallei do not actually become 
acutely ill. A sero-epidemiological survey conducted around Ubon Ratchatani in north-
eastern Thailand showed that many rice farmers in the region were seropositive 
(Suputtamongkol et al, 1994a).  In endemic regions, it was shown that children were 
seroconverted as soon as they came to be exposed to wet soil, and this seroconversion 
occurred at a rate of 25% annually between the ages of 6 months to 4 years (Kanaphun et 
al, 1993). A minority of infected children develop acute suppurative parotitis (infection 
of the parotid salivary gland). 
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After an acute infection, B.pseudomallei can also persist in a dormant stage within 
macrophages for months or years (Egan et al, 1996 and Wong et al, 1995). Under certain 
conditions, recrudescence of the disease can occur. Stressful events such as surgery, 
trauma, burns, diabetic ketoacidosis, cancer and alcoholic binges can trigger the 
recrudescence of the disease. Patients sub-clinically infected run the risk of the 
emergence of the disease in the event of being subject to stressful events as indicated 
above. In one extreme case, a tourist developed fatal melioidosis 24 years after returning 
from Thailand (Wilks et al, 1994).   
 
 3.1.6 Antimicrobial therapy  
 B. pseudomallei shows an intrinsic resistance to a number of classes of antibiotics 
including the aminoglycosides (except kanamycin), early β-lactams, first- and second-
generation cephalosporins, polymixins and macrolides.  
 The conventional antibiotics used for treatment of B.pseudomallei infections 
before 1989 consists of a combination of primarily bacteriostatic drugs: chloramphenicol, 
cotrimoxazole, tetracycline and tetracycline congeners (commonly doxycycline) and on 
occasions, kanamycin (Leelarasamee et al, 1989).  Treatment can last for a period of 6 
weeks to 6 months. Even with treatment using these antibiotics, the prognosis for patients 
suffering from acute melioidosis was grim, with a mortality rate of 82-87% 
(Leelarasamee, 1998).  
 The introduction of ceftazidime as a treatment for B.pseudomallei infections 
brought about a marked decrease in the mortality rate, cutting the rate down by half to  
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35-40%.  Combination treatments, such as ceftazidime-doxycycline therapy, further 
reduced the mortality rate (20%). The current treatment regime for melioidosis patients is 
show in Figure 3.3. As can be observed, the treatment regime for melioidosis patients is 
an arduous one, involving months of antibiotics therapy, both parentally and orally 
administered. Even with this intensive regime, the risk of recrudescence still remains. 
Figure 3.2: Treatment for melioidosis. (Adapted from White, 2003) 
Parenteral treatment 
Ceftazidime 40mg/kg intravenous injection every 8hr, total 120mg/kg per day or 19mg/kg 
intravenous immediately, followed by a continuous infusion of 3.5mg/kg per hr*; or 
imipenem 20mg/kg intravenous injection every 8 hr for a total of 60mg/kg per day 
(meropenem is judged to be equivalent to imipenem). 
* other 3rd generation cephalosporins (e.g. cefotaxime or ceftriaxone) should not be used   
   as these have been associated with increased mortality despite evidence of good in-  
   vitro susceptibility(Chaowagul et al, 1999). 
Parenteral treatment should be given for at least 10 days and should be maintained until 
obvious improvement is observed. The patient can then be switched on to the oral 
regiment. 
Intravenous amoxicillin-clavulanate is also effective and had been associated with 
mortality rates equivalent to the ceftazidime regiment but with higher rate of treatment 
failure (Suputtamongkol et al, 1994 b). 27mg/kg should be given for a total of 162mg/kg. 
Oral treatment 
Adults-treatment of choice is a 4-drug combination of: 
Chloramphenicol (40mg/kg per day in 4 doses) 
Doxycycline (4mg/kg per day in 2 doses) 
Trimethoprim-sulfamethoxazole (10mg and 50mg/kg per day respectively, 2 doses) 
 
Children (less than 8 years) and pregnant women 
Amoxicillin-clavulanate (amoxicillin 30mg/kg per day, clavulanic acid 15mg/kg per day) 
PLUS additional amoxicillin 30mg/kg per day 
 
Oral treatment should be given to complete 20 weeks of treatment 
With the 4 drug regiment prescribed to adults, chloramphenicol is given for only the first 
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Other antibiotics that had been shown to be clinically effective against 
B.pseudomallei include imipenem, meropenem, piperacillin, amoxycillin-clavulanic acid, 
ceftriaxone and cefotaxime. However, the latter two cephalosporins are clinically less 
effective than ceftazidime and are not recommended for use (see Figure 3.2). Much work 
had been done in the search for a more effective treatment regime for melioidosis 
patients. Figure 3.4 and 3.5 illustrates some of the clinical trials that had been carried out 
with various combinations of antimicrobials and their results.
It is not uncommon that melioidosis patients will suffer from a relapse of the 
disease, in spite of being given apparently adequate antimicrobial therapy.  
B.pseudomallei is able to survive and multiply within macrophages (Pruksachartvuthi et 
al, 1990). This ability of the bacteria to sequester within the macrophages protects them 
from exposure to certain antibiotics and hence allows them to recrudesce when the 
environment is permissive. In addition, the bacteria had been shown to produce 
glycocalyx and are able to adhere and form bacterial microcolonies and biofilms, 
especially in environment rich in glucose (Jayanetra et al, 1990) . B. pseudomallei had 
been observed to produce exopolysaccharide glycocalyces and form glycocalyx enclosed 
microcolonies in laboratory media and in lung tissue of infected humans and animals 
(Vorachit et al, 1995). The biofilm formed greatly reduces the penetration of many 
antibiotics and also protects the bacteria from various host defence mechanisms (Vorachit 
et al, 1993). Bacteria embedded in biofilms, and also after release from these, are 
resistant to phagocytosis and phagocytic killing (Donlan, 2002)  
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Table 3.2: Randomised trials of parenteral antibiotics treatment in severe 
melioidosis (Treatment failure refers to the occurrence where the infection is no longer 
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Table 3.3: Randomised trials of oral antibiotic treatment in maintenance treatment 


























































































3.1.7 Antibiotics resistance 
 As mentioned earlier, B.pseudomallei is intrinsically resistant to a wide range of 
antimicrobial agents, including certain classes of β-lactams, aminoglyosides, macrolides 
and polymixins. A multi-drug efflux pump, BpeAB-OprB, has been shown to be 
responsible for the efflux of the aminoglycosides gentamicin and streptomycin, as well as 
the macrolide antibiotic erythromycin (Chan et al, 2004). Another efflux pump 
mechanism, AmrAB-OprA, is also found in B.pseudomallei and is specific for 
aminoglycosides and macrolides (Moore et al, 1999). 
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 B.pseudomallei had also been reported to produce β-lactamases, which confer 
resistance against many β-lactams. Livermore et al (1987), showed that B.pseudomallei 
produced a weakly inducible, membrane associated chromosomal cephalosporinase.  The 
enzyme resembled the cefuroximases of Pseudomonas cepacia and Proteus vulgaris, but 
differed from the Class I cephalosporinases commonly found in Pseudomonas 
aeruginosa and most enterobacteria. It is strongly active against carbenicillin, cefotaxime 
and cefuroxime and can be inactivated quite readily by the β-lactamase inhibitor, 
clavulanic acid. They discovered that ampicillin, carbenicillin, cefoperazone, cefotaxime, 
cefuroxime and cephalothin were hydrolysed in vitro and the addition of clavulanic acid 
increased the activity of these antibiotics by 4 to 64-fold. Cefoxitin, ceftazidime, 
cloxacillin and imipenem, however, were shown to be stable to this enzyme in vitro and 
the addition of clavulanic acid potentiated the activities of these antibiotics by 4-fold or 
less (Livermore et al, 1987).  More recently, genome sequencing has revealed the 
presence of class A, C and D β-lactamase genes and the class A and D β-lactamases had 
already been cloned (Cheung et al, 2002 and Niumsup et al, 2002). In Pseudomanas 
aeruginosa, variants of the class D β-lactamases had been recognised as having a 
significant role in the development of resistance to ceftazidime. In fact, specific 
ceftazidimase activity was reported by Godfrey et al in 1991. Niumsup et al screened 25 
strains of B. pseudomallei for their ability to yield mutants over-expressing β-lactamases 
and found that ceftazidime resistant mutants were selected at high frequency (48%) 
(Niumsup et al, 2002). This is a worrying development as ceftazidime remains the 
antibiotic of choice for treatment of melioidosis. 
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3.2 Salmonella enterica subspecies enterica serotype Typhimurium (Salmonella   
     Typhimurium) 
 
 3.2.1 The genus Salmonella 
 The genus Salmonella is a major cause of bacterial enteric illness in both human 
and animals. The first strain of Salmonella was discovered and reported in 1885 by D.E. 
Salmon, a veterinary surgeon.  By 2001, 2,501 serotypes (serovars) of salmonella had 
been identified (Popoff et al, 2001). The Kauffman-White scheme is used in the 
classification of these serotypes and is adopted in most parts of the world. The Centers 
for Disease Control and Prevention (CDC) of the United States had, prior to 1 January 
2003, employed a modified version of this scheme but have since adopted the original 
Kauffman-White scheme for the classification of Salmonella serotypes in the United 
States (Braden et al, 2002). The antigenic formulae of these serotypes are defined and 
maintained by the World Health Organisation (WHO) Collaborating Centre for Reference 
and Research on Salmonella, based at the Pasteur Institute in Paris, France and updates of 
new serotypes are released annually.  
 Under the Kauffman-White scheme, the genus Salmonella is currently divided 
into 2 species, Salmonella enterica and Salmonella bongori. The species Salmonella 
enterica is further subdivided into 6 subspecies, designated by names or Roman numerals 
as shown in Figure 3.6.  The species Salmonella bongori was previously designated 
subspecies V and is often still referred to as such. 
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 In the case of Salmonella Typhimurium, it a serotype categorised under the 
species enterica and its full name as found in the nomenclature is Salmonella enterica 
subspecies enterica serotype Typhimurium.  As this designation is rather unwieldy, it is 
henceforth referred to as Salmonella Typhimurium (S.Typhimurium), a commonly 
adopted practice now.  
 The species Salmonella enterica consists of numerous serotypes with a wide 
range of hosts, including mammals and birds.  The most highly host-adapted variant is 
the S. enterica serovar Typhi, which only infects humans and higher primates (Geoffrey 
et al, 1960). In contrast, S.Typhimurium, at the other end of the spectrum, has a broad 
host range that encompasses numerous species including humans, livestock, domestic 
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 3.2.2 Characteristics 
 Salmonellae are facultatively intracellular Gram-negative rods, belonging to the 
family Enterobacteriaceae, which includes other genera like Escherichia, Shigella and 
Klebsiella. It is a flagellated, facultatively anaerobic bacillus. Members of the genus 
Salmonella possess 3 major antigens; the H (flagellar) antigen, O (Somatic) antigen and 
also the Vi antigen, which is found only in a few serovars (most importantly, S.Typhi).  
The O and H antigens formed the basis of serotypical classification of salmonella 
serovars. Most salmonellas show phase variation, that is, the bacteria can express 
different H antigens. The flagellar antigens of most salmonellas can occur in one of two 
phases, i.e., the bacteria may express one or the other of 2 possible sets of H antigens. 
 Non-typhoidal salmonellae (species other than S. Typhi, S. Paratyphi and S. 
Choleraesuis) can infect both humans and animals and are common throughout the world. 
Non-typhoidal salmonellosis in man is characterised by diarrhea, nausea, headache, and 
sometimes vomiting. Fever may be present. Bloody diarrhea and invasive disease may 
occur, particularly with certain serotypes. The infection may also present as septicemia, 
abscess, arthritis, cholecystitis and rarely as endocarditis, pericarditis, meningitis, 
pneumonia, or pyelonephritis. 
Animals are usually the reservoir for the bacteria and the disease is commonly 
food-borne, although person-to-person spread is possible. In a study by Mead et al, it was 
determined that 95% of human Salmonella infections were food-borne, and salmonella 
infections accounted for 30% of deaths caused by food-borne pathogens in the United 
States in 1999 (Mead et al, 1999). The most common food that were responsible for      
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Salmonella infections are meat, meat products, eggs and egg products due to the 
intestinal carriage of the bacteria in the animal (Galbraith, 1961). Most of these food 
sources are contaminated during the process of slaughter or butchering, but Salmonella 
enteritidis phage type 4 (PT4) is able to penetrate into developing eggs in the oviduct of 
an infected hen.  
 S.Typhi, however, spreads mainly from person to person via the faecal-oral route 
and has no significant animal reservoirs. Contaminated water is a common vehicle for 
infection. 
 In both typhoidal and non-typhoidal salmonella infections, some infected 
individuals become asymptomatic carriers of the bacteria and this chronic carrier state 
can last from weeks to many years. Chronic faecal excretion is usually associated with an 
infected gall bladder. Chronic renal excretion into the urine may occasionally occur as 
well, typically in patients with chronic disease of the kidneys or urinary tract. 
   
3.2.3 Salmonella Typhimurium 
In July 2000, an abnormal increase in the isolation rate of S.Typhimurium  
definite type (also known as phage type) 104 (DT104) was recorded in Singapore. The 
isolates were found to originate mainly from stool cultures of children below 18 months 
of age.  In total, 33 patients were identified (Ling et al, 2002). 
 Salmonella-induced enterocolitis afflicted an estimated 1.4 million people in the 
United States alone and resulted in the death of more than 500 people annually and is the 
most common cause of death from food-borne illnesses associated with viruses, parasites 
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or bacteria in the United States (Mead et al, 1999). The serotype most commonly 
associated with this disease is Salmonella Typhimurium, which accounted for 26% of all 
Salmonella isolates reported to the US CDC in 1998 (Centers for Disease Control, 1999).   
 As these examples would illustrate, S.Typhimurium is one of the leading causal 
organisms of non-typhoidal salmonellosis.  The problem is even more severe in less 
developed nations.  
 S.Typhimurium infections cause gastroenteritis in humans and usually remains 
localised in the intestine. Healthy humans infected with S.Typhimurium generally 
developed a clinical illness characterised by diarrhoea, vomiting and abdominal pain after 
an initial incubation period of 12 to 72 hours (Blaser et al). The infection is usually 
localised to the intestines and the mesenteric lymph nodes, and incidence of bacteraemia 
is not common and when it does occur, is transient (Mandal et al, 1988).   
 However, this bacterium manifested very differently in a mice model, where it 
caused a systemic infection that bears much similarity to that observed in typhoid fever, 
caused by S.Typhi (Levy et al, 1908 and Loeffler, 1892; cited in Zhang et al, 2003). In 
infected mice, S.Typhimurium spreads systematically via the circulatory system and the 
disease is characterised by severe pathological changes and high bacterial loads in the 
Peyer's patches, mesenteric lymph nodes, in the liver and the spleen (Muller, 1912 and 
Orskov et al, 1929; cited in Zhang et al, 2003). A similar tissue distribution of S.Typhi 
was observed in human typhoid fever patients (Bitar et al, 1985). The immune response 
against the invasion of S.Typhimurium in mice and S.Typhi in humans also bore striking 
similarities and is completely different from that observed in S.Typhimurium 
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enterocolitis in humans (Zhang et al, 2003). Typhoid fever can only be induced 
experimentally in humans and higher primates but not in lower primates or non-primate 
invertebrates, which were resistant (Geoffrey et al, 1960). As such, S.Typhimurium is a 
popular mouse model for the study of invasive salmonella pathogenesis. 
 
 3.2.5 Non-typhoidal salmonellae and HIV 
 Infections by non-typhoidal salmonellae such as S.Typhimurium are usually self-
limited in nature. Only during the instances when the patient demonstrated more serious 
symptoms or had been ill for a long period, would hospitalisation and antimicrobial 
therapy be required.  
 However, in immune-compromised patients such as patients with Acquired 
Immune Deficiency Syndrome (AIDS), an increased frequency of opportunistic 
infections by intracellular pathogens such as non-typhoidal salmonellae was observed, 
with Typhimurium and Enteritidis being the major serotypes isolated (Levine et al, 
1991). In a study of community-acquired septicaemia in HIV-infected children in 
Zimbabwe, it was found that non-typhoidal salmonella was the most common causal 
organism of Gram negative bacillary bacteraemia and that HIV-positive children were 
more likely to suffer from enterobacterial infection compared to HIV-negative children 
(10% vs 0.7%) (Nathoo et al, 1996).  In another study conducted in Kenya, 
S.Typhimurium was among the most commonly isolated organisms from the blood and 
stool samples of HIV-positive patients. In addition, the bacteria was found to be at least 
10 times more common in HIV-positive patients, with S.Typhimurium isolated in 56 
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blood samples of HIV-positive patients compared to 5 in HIV-negative patients while the 
ratio in stool samples was 40:3 (Batchelor et al, 1996). The study in Zimbabwe by Pithie 
et al (1993) also revealed that the mortality rate of HIV-positive patients with non-
typhoid bacteraemia was 40.7% and that salmonella serogroup B, of which included most 
strains of S.Typhimurium, accounted for 37% of the non-typhoidal isolates. It was also 
shown that S.Typhimurium bacteraemia was a common cause of intercurrent infection in 
HIV-positive tuberculosis patients. 
 As such, non-typhoidal salmonella infections, of which S.Typhimurium infections 
formed a significant proportion, represented a serious health problem for HIV-positive 
patients and require immediate remedial therapy when diagnosed. These patients become 
chronically infected and long-term treatment is necessary to suppress bacteraemia. It is 
assumed that chronic infection of the macrophages occurs in HIV infected patients when 
CD4 cells are no longer present in sufficient numbers to provide T-cell help and 
macrophage activation. 
 
 3.2.6 Non-typhoidal Salmonellae and Other Compromised Patients 
 This group of salmonellas can also cause serious invasive infections in other 
patient groups. 
 Individuals at the extremes of life are vulnerable. Salmonellas can cause neonatal 
meningitis, usually acquired at delivery from faecal contamination from the mother. The 
elderly suffer from bacteraemia more frequently than is found in younger groups, and this 
may itself cause morbidity, or it may cause a chronic infection of the atheromatous 
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plaques inside major arteries, which may in time necessitate major vascular surgery and 
vessel grafting. Patients with sickle cell disease have a particular predisposition to 
develop salmonella osteomyelitis.  
 
 3.2.7 Therapy 
  As mentioned previously, non-typhoidal salmonellosis in healthy 
individuals is usually self-limiting and does not require any antimicrobial therapy. Only 
in severe cases when the illness had been prolonged or if complications arose, would 
antimicrobial therapy be indicated. Of course, antibiotic treatment would be required for 
patients suffering from typhoid fever. Chloramphenicol was the first antibiotic to be used 
successfully to clear a Salmonella infection. It remained a drug of choice in many 
developing countries due to the low cost (Acharya et al, 1995). Ampicillin and 
trimethoprim-sulfonamide have also been used successfully against infection by 
salmonellas. The newer antibiotics such as certain cephalosporins and fluoroquinolones 
are also highly effective. Ceftriaxone, a third-generation cephalosporin, had been proven 
highly effective and has become the standard for treatment of typhoid fever in many parts 
of the world (Soe et al, 1987). The new azalide class of antibiotics offered a new 
alternative to the treatment options for salmonellosis. One member of this class, 
azithromycin, had been tested in a random clinical trial and was shown to be effective in 
the treatment of Salmonella Typhi infection in children (Frenck et al, 2000). 
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 Salmonella are facultatively intracellular bacteria. The ability of such bacteria to 
sequester itself inside the host macrophages could lend additional protection against the 
effect of an otherwise effective antibiotic (Hand et al, 1986). 
Chiu et al (1999) tested a number of antibiotics in order to determine their 
efficaciousness against intracellularly localised non-typhoidal salmonella (within P338D1 
mouse macrophage cell line). It was found that gentamicin, as expected, penetrated the 
infected cells very poorly indeed, while ofloxacin, azithromycin, chloramphenicol and 3 
β-lactams antibiotics, ampicillin, cefixime and ceftriaxone all exhibited bacteriostatic 
activity when present extracellularly at concentrations equivalent to their Minimum 
Inhibitory Concentrations (MIC). Exposure to extracellular levels of ofloxacin and 
azithromycin at 10xMIC resulted in the decrease in the number of viable bacteria while 
exposure to similar levels of chloramphenicol and the 3 β-lactams failed to produce a 
bactericidal response. As the ability of chloramphenicol and β-lactams like ceftriaxone to 
eliminate intracellular salmonella were shown to be poor, fluoroquinolones and 
azithromycin seemed to be viable alternatives for salmonella therapy. However, as 
arthropathy had been observed when young animals were given fluoroquinolones, these 
drugs are not approved for use in children younger than the age of 18. 
 
 3.2.8 Antimicrobial resistance 
 Antibiotics are used as therapeutic agents not only for humans but for animals as 
well. Antibiotics had been used for livestock since the 1940s, not just as therapeutic 
agents but soon were also used in lower dosage as supplements to promote growth of 
 32
                                             Studies on Antibiotics Action on Intracellular Bacteria 




livestock. This created a selective pressure acting on the micro-organisms colonising 
these livestock and unsurprisingly, researchers soon found correlation between the 
introduction of antibiotics for livestock and the appearance of resistant strains (Smith et 
al, 1957). In addition, modern large scale farming of animals which began in the 1960s in 
Britain encouraged the mixing of animals from various origins and this further 
encouraged the spread of infections, including S.Typhimurium. An outbreak of 
S.Typhimurium phage typeDT29 in cows occurred in Britain from 1964 to 1966.  
Antibiotics were used in treatment and by 1963, drug resistance was observed in human 
and bovine DT29 isolates. By 1965, resistance to one or more antibiotic was recorded in 
99.7% of DT29 isolates (Anderson, 1968). Over time, tight controls over antibiotics 
usage allowed for the elimination of the threat of S.Typhimurium DT29 but over the 
years, epidemic outbreaks of multi-resistant S.Typhimurium involving S.Typhimurium 
DT 204, DT 193 and DT 204c occurred. More recently, surveys had shown that the 
percentage of multiply resistant S.Typhimurium isolates had increased from 5% in 1981 
to 19% in 1990 (Threlfall et al, 1993). In 1984, a multiply resistant strain of 
S.Typhimurium DT104 was isolated and began to spread rapidly around the world, 
reaching epidemic proportions in the United States and the United Kingdom in the 1990s. 
This new strain was resistant to at least 5 antibiotics. The initial isolates were shown to be 
resistant to ampicillin, chloramphenicol, streptomycin, sulphonamides and tetracyclines. 
The resistance genes were found to be chromosome-encoded (Threlfall et al, 1994) 
unlike most resistance cases which involved plasmid-mediated resistance gene transfers 
(Anderson et al, 1965 and Threlfall et al, 1986). This caused some worry as this 
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increased the likelihood that the resistance genes would be maintained even in the 
absence of selective pressures. Resistance to trimethoprim soon appeared as well and 
isolates were soon encountered that also showed a markedly decreased susceptibility to 
ciprofloxacin (Threlfall et al, 1997).  What was more worrying was that infection with 
S.Typhimurium DT104 was observed to be more serious than that caused by other non-
typhoid salmonella, with a higher rate of hospital admissions (36%) and mortality rates 
(3%) (Wall et al, 1994).  
 
 3.3 Objectives 
The objective of this project is to evaluate the activity of a number of antibiotics 
against intracellular B.pseudomallei and S.Typhimurium using an in vitro model with 
J774.1 murine macrophage cells as hosts. Combinations of antibiotics were also tested for 
possible synergism. 
In addition, possibility of alternative and adjunctive therapy using cytokines was 
also explored. Due to the lack of time, only interferon-γ was tested for its ability to 
stimulate the clearance of intracellular bacteria via the stimulation of the host cells’ own 
defence mechanisms. Combinations of interferon-γ stimulation of cells with various 
antibiotics were also tested against intracellular S. Typhimurium for possibility of 
synergistic action.  
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4.MATERIALS AND METHODS 
 
4.1 Strains used 
 A. Burkholderia pseudomallei ATCC 15682 
 B. Salmonella enterica subspecies enterica serotype Typhimurium 
(Salmonella Typhimurium) ATCC 14025 
 Identities of bacterial strains were re-confirmed using API 20NE (for 
Burkholderia pseudomallei) and API 20E (for Salmonella Typhimurium). Routine 
subculture of Salmonella Typhimurium onto Hektoen selective enteric agar was also 
carried out as further quality control tests: typical black (H2S producing) colonies were 
observed. 
Bacteria were routinely cultured on nutrient agar (Oxoid) and incubated at 37˚C 
for 48hr (B. pseudomallei) or 24hr (S.Typhimurium).  
For experimental use, a colony of bacteria was inoculated into Brain Heart 
Infusion (BHI) broth and incubated overnight (12hr) at 37˚C prior to inoculation into 
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4.2 Cell Lines 
 A. J774A.1 Murine macrophage cell line (ATCC TIB-67) 
  Cells were maintained in Dubelcco’s Modified Eagle’s Medium (JRH) 
enriched with 5% Fetal Bovine Serum (Hyclone) and 20mM Hepes buffer (Sigma), 
hereafter referred to as DMEM and incubated at 37˚C with 5% carbon dioxide.  
  Cell line was discarded upon reaching 25 passages and a new batch 
thawed out from stocks frozen in liquid nitrogen. 
 B. THP-1 Human monocyte cell line (ATCC TIB202) 
  Cells were maintained in RPMI 1640 (Sigma) enriched with 5% Fetal 
Bovine Serum (Hyclone), 2mM L-glutamine (Sigma) and 20mM Hepes buffer (Sigma), 
hereafter referred to as RPMI. Cells were incubated at 37˚C with 5% carbon dioxide. 
  Cell line was discarded upon reaching 25 passages and a new batch 
thawed out from stocks frozen in liquid nitrogen. 
 
4.3 Determination of Minimum Inhibitory Concentration (MIC) (Microtitre Plate  
      Assay) 
 NTCC broth microdilution method was used (Performance Standards for 
Antimicrobial Susceptibility Testing (NCCLS), 2004). 
 Cation-adjusted Muller-Hinton broth (Difco) containing 22.5mg/ml Ca2+ and 
11mg/ml Mg2+ with a final pH of 7.3 was used as the dilution medium in this assay. 
 The antibiotic to be tested was made up in Cation-adjusted Muller-Hinton broth 
(CAMHB) to twice the highest concentration that was to be used in the assay. 
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 Meanwhile, a bacterial suspension of McFarland 0.5 was made up in saline. This 
suspension would contain approximately 108cfu/ml bacteria. A 1:100 dilution of the 
bacterial suspension was then made, using CAMHB as the dilution media. Hence, the 
concentration of bacteria in this suspension was now approximately 106cfu/ml.  
 The microtitre plate wells from no. 2 till 12 were filled with 50μl CAMHB. 100μl 
of the antibiotic suspension to be tested was dispensed into the first well and 
subsequently, 50μl of this was transferred to the second well and mixed well with the 
50μl CAMHB already present. This was then repeated until the last well (no.12), where, 
after mixing thoroughly, 50μl of the suspension within the well was removed and 
discarded. 
 50μl of the bacterial suspension prepared above was then added to each well and 
the bacterial suspension was mixed well with the antibiotic suspension already present by 
carefully pipetting up and down.  
 Control wells, one with the bacterial suspension (in CAMHB) only and another 
with the antibiotic-CAMHB suspension, were also prepared. The former was prepared to 
ensure that the bacterial growth was not inhibited by any other factor other than the test 
antibiotic while the latter is performed to check for possible contamination of the 
antibiotic stock or the CAMHB by another type of bacteria which could result in an 
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4.4 Intracellular Antibiotics Killing Assay 
 A suspension of  J774.1 cells in Leibovitz medium enriched with 3% Fetal Bovine 
Serum (Hyclone), 4 mM glutamine (Sigma) and 50 mM Hepes buffer pH7.5 (Sigma) 
(hereafter referred to as L15 medium) was adjusted to the density of 4x106 cells/ml. The 
cell suspension was infected with an overnight bacteria broth to a ratio of 1 overnight 
culture to 1000 cell suspension. The cell and bacteria suspension was incubated at 37˚C 
for 30min to allow the bacteria to infect the cells. 
 100 µg/ml of gentamicin was added to the suspension containing J774.1 and 
Salmonella Typhimurium. Aminoglycosides including gentamicin and kanamycin were 
rapidly bactericidal antibiotics with poor cell penetration (O’Grady et al, 1997) and are 
commonly utilized to kill any remaining extracellular bacteria without compromising the 
intracellular bacteria population. Kanamycin was used in assays with Burkholderia 
pseudomallei as the MIC value for kanamycin was lower than gentamicin. Gentamicin is 
most commonly used in such assays but kanamycin has also been employed to kill 
extracellular Burkholderia cepacia (Saini et al, 1999). 100µg/ml kanamycin was used. 
The cells were incubated with the gentamicin or kanamycin for a further 30min at 37˚C 
to eliminate most the extracellular bacteria present. 
 The cells were washed by centrifugation at 400g for 10min (Sigma 3-15 
centrifuge) and then resuspended in PBS. The washing step is repeated twice to ensure 
the complete removal of any aminoglycoside (gentamicin or kanamycin) present in the 
system. The infected cells were then resuspended in L15 to a density of 4x106cells/ml. 
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 The infected cells were then aliquoted into Eppendorf tubes and incubated with 
the desired concentrations of the test antibiotics. An antibiotic free control was also set 
up. However, this antibiotic free control would not allow for the differentiation of 
intracellular and extracellular bacterial propagation and hence a further control was 
usually set up. The second control involved the incubation of the infected cells with 
100µg/ml gentamicin for Salmonella Typhimurium or 100µg/ml kanamycin for 
Burkholderia pseudomallei. This second control was included to eliminate completely 
any extracellular population of bacteria..  
 The infected cells subjected to the various test conditions were then incubated on 
a roller at 37˚C and sampled at set intervals.  
The cells were pelleted by centrifugation at 13,000 rpm (15,000g) for 5min using 
a Jouan A-14 microcentrifuge and the supernatant was discarded. The cell pellet was 
resuspended in distilled water and allowed to stand for 5min to facilitate J774.1 cell lysis, 
releasing the intracellular bacteria. 
 The appropriate dilutions of the cell lysate were plated out onto nutrient agar and 
the number of bacteria present was enumerated using the method of Miles and Misra.  
 For S.Typhimurium, we were also able to test another cell line, THP-1 with the 
bacteria. The methods used were identical. 
 
4.6 Miles and Misra 
 The method of Miles and Misra was described in the Journal of Hygiene in 1938. 
Five 20μl drops of an appropriate dilution of the cell lysate was seeded onto a nutrient 
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agar plate and incubated at 37°C for 24 hours (48 hours for B.pseudomallei). Dilutions 
giving 5-50 colonies were counted and the number of bacteria per ml determined: 
No. of bacteria / ml = no.of colonies x 20 x dilution factor 
 
Figure 4.1: Diagrammatic explanation of the intracellular antibiotic killing assay. 
J774.1 (or THP-1) cells were suspended in L15 medium. The test organism (B. 
pseudomallei or S.Typhimurium) were added and allowed to infect the host cells. 
The addition of kanamycin (against B.pseudomallei) or gentamicin 
(S.Typhimurium) resulted in the killing of any extracellular bacteria. However, due 
to the poor cellular penetration of these aminoglycosides, the intracellular 
population of the bacteria were protected from their effect. The cells were then 
washed and the test antibiotics added. 
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4.5 Extracellular Antibiotics Killing Assay 
 L15 medium was inoculated with an overnight culture of bacteria to a ratio of 1 
bacteria culture to 1000 L15 medium. This was then aliquoted into Eppendorf tubes and 
exposed to the appropriate concentrations of the test antibiotics. An antibiotic free control 
was also performed. These were then incubated at 37˚C on a roller and sampled at set 
intervals. 
 The number of bacteria present in each sample was enumerated by plating onto 
nutrient agar according to the method of Miles and Misra. 
 
4.6 Effect of Interferon-γ on killing of intracellular bacteria 
 Cell cultures were preincubated with murine interferon-γ (from Sigma; made up 
in PBS with 0.5% Bovine Serum Albumin in PBS) of the desired concentration for12hr. 
The cells were incubated in DMEM in an incubator at 37°C with 5% carbon dioxide.  
 Following the incubation with IFN-γ, the cells were infected and processed as was 
shown in 4.4 (above). 
Gentamicin was used to suppress the growth of extracellular bacteria during the 
assay. As a control, another batch of cell cultures were preincubated at the same 
conditions for 12hr with 0.5% BSA in PBS before the same assay was performed 
concurrently. 
When testing for any synergistic or antagonistic effects with antibiotics, 
interferon-treated cells and non-treated cells were both incubated with desired 
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concentrations of the test antibiotics and the numbers of bacteria present after 
predetermined intervals were compared using the method of Miles and Misra.  
 
4.7 Acridine-orange staining 
 J774.1 cells in L15 (4x106cells/ml) were infected with S.Typhimurium for 30min. 
These cells were then washed once with PBS by centrifugation at 110g for 7minutes and 
then stained with 0.01% acridine orange for 45 seconds. The stained cells were then 
washed thrice with PBS (100g / 7 min) to remove the stain and then quenched with 
0.05% crystal violet for 20 minutes. A drop of the cell suspension was then placed onto a 
slide and covered with a coverslip. The slide was the viewed under UV light using an 
Olympus BX60 microscope and S.Typhimurium could be observed as green fluorescent 
rods within the J774.1 cells. 
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5. RESULTS AND DISCUSSION  
 Firstly, for the experiments conducted with B.pseudomallei, the choices of 
antibiotic concentrations were based mainly on the achievable serum concentration in 
vivo and hence considered in the form of μg/ml rather than as multiples of the MIC 
values. This was due to the high MIC values for most antibiotics against B.pseudomallei 
and hence, the maximum achievable serum level must be a major consideration before 
deciding if the drug was potentially useful in clinical therapy.  As such, the 
concentrations of antibiotics used were chosen by looking at the highest achievable serum 
level as the upper limit rather than at the MIC value. Therefore, unlike the results for 
S.Typhimurium which began at 1xMIC, for B.pseudomallei, the antibiotic concentrations 
often do not begin at 1xMIC. 
 When the work moved on to S.Typhimurium, it was found that the MIC values for 
most antibiotics against the bacteria were relatively low. As such, achievable serum 
levels of the antibiotics were commonly more than adequate and hence it was decided 
that it would be more useful to look at the results as multiples of MIC values instead. The 
choices of antibiotic concentrations for S.Typhimurium began at the lower limit of 
1xMIC and increase in multiples of MIC. 
 
5.1 Melioidosis 
5.1.1 Minimum Inhibitory Concentrations 
 The minimum inhibitory concentrations for all the antibiotics tested against 
B.pseudomallei ATCC 15682 are listed in the table below. Duplicates were performed for 
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each MIC determination on two occasions and the values obtained for both sets were 
identical and consistent with MIC values found in publications. 
 
Table 5.1: Minimum Inhibitory Concentration (MIC) for the antibiotics used.   
















(fixed at 8:1 ratio as supplied 
for intracellular use) 
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5.1.2 Antibiotics Killing Assay 
 The experiment was conducted in two stages. Initially, sampling was carried out 
every 2 hours for 8 hours followed by a final sampling at 24hr (time-course assay). A 
graph comparing the log number of viable bacteria against time was plotted for the 
various concentrations of the antibiotics used (example in Figure 5.2).  As performing a 
triplicate experiment involving all the time points was too time and resource consuming, 
the data from the time-course sampling was observed and the time interval of 6hr was 
chosen as the end point for triplicate experiments. In these experiments, the killing assays 
were conducted in triplicates and plate counts to determine the number of viable bacteria 
were carried out at 0hr and 6hr. 
 Note: As this project was ended prematurely, we had not had the opportunity to 
repeat the assays shown below to prove that the data obtained were completely 
reproducible. However, the single-point time course experiments yielded data consistent 
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A) Kanamycin  
 
Figure 5.1: Graph depicting the killing of extracellular B.pseudomallei by 
kanamycin (Time course over 24hr).  


















Control Kanamycin 50 µg/ml Kanamycin 100µg/ml
 
 Figure 5.1 is a graph plotting the log of colony-forming units (cfu/ml) against the 
incubation time. The graph shows the log number of B.pseudomallei (colony-forming 
units) per ml plotted against time (hours).  Sampling was done every 2 hours from 0hr to 
8hr and a final sample at 24hr. 
 As can be seen in Figure 5.1, kanamycin killed extracellular B.pseudomallei in a 
time- and concentration-dependent manner over the first 6 hours. Almost complete kill 
was observed at the higher concentration tested (100μg/ml). However, there was a small 
increase in viable bacterial count at both kanamycin concentrations tested in the period 
between 6 to 24 hours. It had been shown that this was not caused by the degradation of 
the antibiotic as bioassays carried out showed no decrease in kanamycin activity when 
the antibiotic was incubated for 24hr in similar conditions as above (results not shown). 
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 A possible explanation for the small increase between the 6 and 24 hour time 
points is that an inducible antibiotic resistance mechanism had become active during this 
period. A possible mechanism could be the efflux pumps mechanisms that were reported 
previously (Chan et al, 2004; Moore et al, 1999). These efflux pumps had been shown to 
play a role in the removal of aminoglycosides from the bacterial cell. 
   
Figure 5.2: Graph depicting the activity of kanamycin against intracellular 
B.pseudomallei (Time-course over 24hr) 


















Control Kanamycin 100 µg/ml
 
 Kanamycin at 100μg/ml had no effect on the intracellular survival of 
B.pseudomallei over the test period of 24 hours. 
 Aminoglyoside antibiotics, including gentamicin and kanamycin, have been 
shown to have generally poor activity against intracellular bacteria as they penetrate the 
host cell membrane poorly. 
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 In many published papers measuring intracellular killing of bacteria, gentamicin 
is used to kill the remaining extracellular bacteria. However, the MIC of gentamicin 
against B.pseudomallei is very high and kanamycin (which had a lower MIC value 
against B.pseudomallei) was tested instead for its suitability in the same role. As can be 
seen from the results above, kanamycin was shown to be rapidly bactericidal against 
extracellular B.pseudomallei at the higher concentration of 100μg/ml and also have poor 
penetration into J774.1 host cells; hence the intracellular population was protected from 
killing.  
 For most of the following intracellular assays, we included two controls: an 
antibiotic-free control and a second control which contain 100μg/ml of kanamycin. The 
time-dependent increase in bacterial numbers observed in the first control (without 
antibiotics) was representative of bacterial growth both intracellular and extracellular. To 
better isolate the growth rate of only the intracellular bacteria, the second control was 
introduced. The kanamycin added would eliminate any extracellular bacteria present and 
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 B) Amoxycillin-clavulanic acid 
i) Amoxycillin-clavulanic acid Against Extracellular B.pseudomallei 
 
Figure 5.3: Graph depicting the activity of amoxicillin-clavulanic acid against  
extracellular B.pseudomallei (Time-course showing the bacterial numbers measured 
over 24hr).  



















Amoxycillin  (8 µg/ml) + clavulanate (1.6 µg/ml)  1xMIC
Amoxycillin  (16 µg/ml) + clavulanate (3.2 µg/ml) 2xMIC
Amoxycillin  (48 µg/ml) + clavulanate (9.6 µg/ml) 6xMIC
Amoxycillin (80 µg/ml) + clavulanate (16 µg/ml) 10xMIC  
Amoxycillin plus clavulanic acid was shown to be effective in killing 
B.pseudomallei over 24hr in an extracellular in vitro assay. Compared to kanamycin, 
there was no concentration-dependent increase in killing and this was consistent with 
many other observations of the effect of β-lactam antibiotics against a variety of bacterial 
target (Livermore DM, Williams JD; Chapter 12 in Lorian, 1996).  
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Figure 5.4: Bar Chart depicting the activity of amoxicillin-clavulanic acid against 
extracellular B.pseudomallei (Triplicate results showing the % change in bacterial 
numbers after 6hrs of incubation). The error bars show the standard deviation 
between the readings obtained for each set of the triplicate (in the graph below, the 
error bars were too small to be visible). (An antibiotic free control was also carried 
out in triplicates but the results are not shown in these graphs) 
 


























Amoxycillin (8 µg/ml) + clavulanate (1.6 µg/ml) 1xMIC
Amoxycillin (16 µg/ml) + clavulanate (3.2 µg/ml) 2xMIC
Amoxycillin (48 µg/ml) + clavulanate (9.6 µg/ml) 6xMIC
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A brief explanation of data presentation in Figure 5.4:  The results of a series of 3 
simultaneous determinations were plotted. Sampling was conducted at 0hr and 6hr. The 
time of 6hr as the end point was chosen based on the earlier experiment involving 
kanamycin (Figure 5.2) which showed that the number of extracellular bacteria at that 
point was almost below the sensitivity of the assay system. In addition, the test antibiotics 
used are at least 1xMIC (often much higher) in order to ensure that extracellular bacteria 
are killed or at least rendered static. This would suggest that most, if not all, the bacteria 
counted at this time existed as an intracellular organism.  
In extracellular killing assays as that in Figure 5.4, there is no need for a 
kanamycin control but the same time points were used to allow comparison with the 
intracellular killing assays. 
The bar chart above depicts the % change in the bacterial numbers as calculated 
from the equation below: 
(No. of bacteria at 6hr) – (No. of bacteria at 0hr) 
                             _______________________________________         x 100% 
 
(No. of bacteria at 0hr) 
 
Error bars found on the charts indicate the standard deviation of the bacterial 
counts obtained from each sample. 
  
The triplicate assays were performed and bacterial numbers were determined at 
0hr and 6hr.  Almost complete kill was noted for all four concentrations tested. 
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ii) Amoxycillin-clavulanic acid Against Intracellular B.pseudomallei 
 
Figure 5.5: Graph depicting the activity of amoxicillin-clavulanic acid against  
intracellular B.pseudomallei within J774.1 cells (Time-course showing the bacterial 
numbers measured over 24hr). 
Amoxycillin-clavulanic acid Killing Assay vs Intracellular 



















Amoxycillin (8 µg/ml) + clavulanate (1.6 µg/ml) 1xMIC Amoxycillin (16 µg/ml) + clavulanate (3.2 µg/ml) 2xMIC
Amoxycillin (48 µg/ml) + clavulanate (9.6 µg/ml) 6xMIC Amoxycillin (80 µg/ml) + clavulanate (16 µg/ml) 10xMIC
 
The combination of amoxycillin and clavulanic acid was next tested in the 
intracellular assay system. Both antibiotic-free and kanamycin controls were included. 
The kanamycin control is assumed to represent the intracellular B.pseudomallei 
population.  
There is evidence of low level intracellular killing at the lowest concentration 
tested and a dose-dependent increase was observed as intracellular killing was found to 
increase with increasing concentration of co-amoxyclav. As β-lactams often do not show 
dose-dependent killing (Livermore DM, Williams JD; Chapter 12 in Lorian, 1996), this 
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could be due to the fact that the entry of the antibiotic into the cells were limited by the 
barrier of the cell membrane. At lower concentrations, only a low concentration of the 
antibiotic could gain access to the cell interior and kill the bacteria nearest to the 
membrane while those deeper into the cell interior may be subjected to much lower 
concentrations and the rate of killing was countered by the rate of growth of these 
bacteria. When a higher concentration was used, the high concentration gradient between 
the two sides of the membrane could have led to significantly higher concentration of 
amoxicillin-clavulanic acid gaining access into the host cell and permeate the entire cell, 
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Figure 5.6: Bar Chart depicting the activity of amoxicillin-clavulanic acid against 
intracellular B.pseudomallei within J774.1 cells (Triplicate results showing the % 
change in bacterial numbers after 6hrs of incubation). The error bars show the 
standard deviation between the readings obtained for each set of the triplicate. 
Amoxycillin-clavulanic acid Killing Assay vs 


























Amoxycillin (8 µg/ml) + clavulanate (1.6 µg/ml) 1xMICl
Amoxycillin (16 µg/ml) + clavulanate (3.2 µg/ml 2xMIC)
moxycillin (48 µg/ml) + clavulanate (9.6 µg/ml) 6xMIC
Amoxycillin (80 µg/ml) + clavulanate (16 µg/ml) 10xMIC
 
 Triplicate measurements of bacterial numbers at 0hr and 6hr were made and the 
results expressed as % changes in cell numbers as was done for the extracellular assay 
results. Amoxycillin plus clavulanic acid caused a concentration-dependent decrease in 
intracellular bacterial numbers.  
Note: The bacterial numbers measured in the time-course experiments were 
expressed on a logarithmic scale whereas the results for the triplicate experiments employ 
linear scale. Hence, the survival of a small number of bacteria translates to a near 100% 
kill in the bar charts. 
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   Amoxycillin-clavulanic acid (also known as Augmentin) can achieve a peak 
serum level of 7.6μg/ml amoxycillin and 2.3μg/ml clavulanic acid for an oral dose of 
500mg amoxycillin/ 500mg clavulanic acid (Lorian, 1996). From the data sheet of the 
product, the intravenous administration of the drug can achieve even higher serum levels, 
with a dose of 1000mg amoxicillin and 200mg clavulanic acid capable of producing a 
peak serum level of 105.4μg/ml amoxicillin and 28.5μg/ml clavulanic acid. Hence, 
considering the MIC of this drug against B.pseudomallei, it would suggest that the 
intravenous route would be most advantageous for the administration of this drug. 
 Also, comparison between Figure 5.4 and Figure 5.6 shows that a clear difference 
exists in the kills recorded at lower multiples of MIC between extracellular and 
intracellular bacteria. There is a reduction in the bactericidal activity observed when the 
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i) Ceftazidime Against Extracellular B.pseudomallei 
 
Figure 5.7: Graph depicting the activity of ceftazidime against extracellular 
B.pseudomallei (Time-course showing the bacterial numbers measured over 24hr). 



















Control Ceftazidime 5 µl/ml 2.5xMIC Ceftazidime 50µl/ml 25xMIC
 
 A time-course of extracellular killing shows that ceftazidime causes an 
approximately 2 log kill over the course of 24 hours and the killing was dose-dependent, 
with a higher killing rate observed at the higher concentration.  
 The killing was observed to “plateau” during the longer period of incubation from 
8 hr to 24hr. In time-kill studies done by Sookpranee et al (1991), it was shown that 
B.pseudomallei, when treated with ceftazidime equivalent to 1xMIC, showed an initial 
decrease in numbers but the bacterial numbers actually “bounced back” upon longer 
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incubation.  This phenomenon, noted both in the results of this study and that reported by 
Sookpranee et al (1991), may be the result from an inducible chromosomal β-lactamase 
present in B.pseudomallei (Godfrey et al, 1991). 
 
Figure 5.8: Bar Chart depicting the activity of ceftazidime against extracellular 
B.pseudomallei (Triplicate results showing the % change in bacterial numbers after 
6hrs of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 






























Ceftazidime 5µg/ml 2.5xMIC Ceftazidime 10µg/ml 5xMIC
Ceftazidime 20µg/ml 10xMIC Ceftazidime  50 µg/ml 25xMIC
 
The result of the triplicate repeats of the extracellular assay (including the range 
of concentrations not covered in the time-kill assay) with sampling done at 0hr and 6hr 
confirmed that killing occurred at all the concentration tested. It also confirmed that the 
killing was dose-dependent to a small degree, with a small increase in killing when the 
dosage was increased.  
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ii) Ceftazidime Against Intracellular B.pseudomallei 
 
Figure 5.9: Graph depicting the activity of ceftazidime against intracellular 
B.pseudomallei within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 



















Control Kanamycin 100 µl/ml
Ceftazidime 5 µl/ml 2.5xMIC Ceftazidime 10 µl/ml 5xMIC
Ceftazidime 20 µl/ml 10xMIC Ceftazidime 50 µl/ml 25xMIC  
 
The time-course intracellular assay suggests a small dose-dependent decrease in 
bacterial numbers over the course of 24 hours but the killing observed was below that 
observed in the extracellular killing assays. 
It is also interesting that the decline in the killing rate observed over the period of 
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Figure 5.10: Bar Chart depicting the activity of ceftazidime against intracellular 
B.pseudomallei within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hrs of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. 





























Kanamycin 100µg/ml Ceftazidime 5 µg/ml 2.5xMIC
Ceftazidime 10µg/ml 5xMIC Ceftazidime 20µg/ml 10xMIC
Ceftazidime 50µg/ml 25xMIC
 
 The results from the triplicate intracellular assays confirmed the earlier 
observation that ceftazidime was less effective against intracellular bacteria compared to 
extracellular bacteria. However, a sufficiently high dosage of ceftazidime (50μg/ml) is 
shown to reduce the number of intracellular B.pseudomallei by up to 20%. The 
achievable in vivo serum concentration of ceftazidime is as high as 105μg/ml when 
administered intravenously (Lorian, 1996), which means that this antibiotic can still be 
administered in sufficiently high levels to be effective in killing the intracellular bacteria, 
 59
                                             Studies on Antibiotics Action on Intracellular Bacteria 




even given the reduced efficacy against intracellular bacteria compared to extracellular 
bacteria.   
 In clinical situations, ceftazidime is the treatment drug of choice for melioidosis 
and is given for a minimum period of 10 days, to be followed by an oral therapy with 
other drugs such as chloramphenicol or doxycycline. It is a limitation of our in vitro 
system that the observations can only be made up to 24hr, after which the J774.1 cells 
begin to die and lose their membrane integrity. However, the results obtained here do 
show that high extracellular concentrations of ceftazidime can penetrate the cells in 
sufficiently high levels to kill a proportion of the intracellular B.pseudomallei by 6 hours.  
An in vivo study using animal models for longer periods could be carried out to 
determine in complete clearance of the intracellular antibiotics were indeed achieved with 
the current therapy. 
  
D) Ceftriaxone 
To avoid cluttering due to the large number for graphs, the data for some less 
significant antibiotics were omitted from this section. These graphs are available at the 
Appendix 1.1 (Figures A1.1-A1.4).  
Against B.pseudomallei, ceftriaxone showed a dose-dependent killing in both the 
extracellular and intracellular environment but in both environments, complete 
elimination of the bacteria was not observed. And as could be expected, the antibiotic 
was much less effective in killing intracellular bacteria localised within the J774.1 host 
cells, being able to reduce the bacteria numbers only by a small fraction even at the 
highest concentration tested.   
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An intravenous infusion of 1g of ceftriaxone can achieve serum levels up to 100-
175μg/ml. It can be seen in the results that the administration of 100μg/ml of ceftriaxone 
can produce an intracellular kill of up to 30%. However, as mentioned previously, 




i) Ciprofloxacin against extracellular B.pseudomallei 
Figure 5.11: Graph depicting the activity of ciprofloxacin against extracellular 
B.pseudomallei (Time-course showing the bacterial numbers measured over 24hr). 
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Figure 5.12: Bar Chart depicting the activity of ciprofloxacin against extracellular 
B.pseudomallei (Triplicate results showing the % change in bacterial numbers after 
6hrs of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 


























Ciprofloxacin 5µg/ml 5xMIC Ciprofloxacin 10µg/ml 10xMIC
Ciprofloxacin 20µg/ml 20xMIC Ciprofloxacin 50 µg/ml 50xMIC
 
Figures 5.11 and 5.12 showed that ciprofloxacin was effective in killing 
B.pseudomallei over the course of 24 hours and that the killing was usually dose-
dependent, although a slight paradoxical effect as seen above was occasionally observed 
in which the highest concentration showed reduced efficacy compared to lower 
concentrations of ciprofloxacin. This paradoxical effect was reported in Lewin et al 
(1991), where it was found that the bactericidal ability of some quinolones increase up to 
an optimal bactericidal concentration and then declines due to the inhibition of RNA 
synthesis occurring at these high levels (RNA synthesis is required for the full activity of 
these quinolones).  
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 ii) Ciprofloxacin against intracellular B.pseudomallei 
 
Figure 5.13: Graph depicting the activity of ciprofloxacin against intracellular 
B.pseudomallei within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 


















Control Kanamycin 100 µl/ml
Ciprofloxacin 5 µg/ml 5xMIC Ciprofloxacin 10 µg/ml 10xMIC
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Figure 5.14: Bar Chart depicting the activity of ciprofloxacin against intracellular 
B.pseudomallei within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hrs of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. (The results 
for the kanamycin control was omitted for this set as the value was too high and 
would result in a significant loss of resolution in the graphs for ciprofloxacin killing) 

























Ciprofloxacin 5µg/ml 5xMIC Ciprofloxacin 10µg/ml 10xMIC
Ciprofloxacin 20µg/ml 20xMIC Ciprofloxacin 50 µg/ml 50xMIC
 
 
Ciprofloxacin also showed time- and concentration-dependent killing in the 
intracellular model. At higher concentrations, virtually complete killing was achieved. 
Depending on the dose regime, various Cmax values have been reported for 
ciprofloxacin. A peak serum level of approximately 4μg/ml for an intravenous dose of 
400mg was reported (Lettieri et al, 1992) 
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The antibiotic penetrates the host cell well, as can be seen in the above results, 
and may have a role in the prevention and treatment of melioidosis, particularly as a part 




i) Chloramphenicol against extracellular B.pseudomallei 
 
Figure 5.15: Graph depicting the activity of chloramphenicol against extracellular 
B.pseudomallei (Time-course showing the bacterial numbers measured over 24hr). 



















Control Chloramphenicol 20 µg/ml
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Figure 5.16: Bar Chart depicting the activity of chloramphenicol against 
extracellular B.pseudomallei (Triplicate results showing the % change in bacterial 
numbers after 6hrs of incubation). The error bars show the standard deviation 
between the readings obtained for each set of the triplicate. 



























Chloramphenicol 20 µg/ml Chloramphenicol 50 µg/ml
Chloramphenicol  100 µg/ml
 
Chloramphenicol, widely regarded as a bacteriostatic drug, was shown to be 
bactericidal when introduced at very high concentration. When sufficiently high 
concentrations were applied, slightly dose dependent killing was observed, though this 
was only apparent later in the incubation period. Although dose-dependency is apparent 
in the triplicate results, the time-course results showed only a slight increase in 
bactericidal activity at 6 and 8 hours, and by 24 hours, dose-dependent killing was not 
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ii) Chloramphenicol against intracellular B.pseudomallei 
 
Figure 5.17: Graph depicting the activity of chloramphenicol against intracellular 
B.pseudomallei within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 
Chloramphenicol Killing Assay vs Intracellular 


















Control Kanamycin 100 µ/ml
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Figure 5.18: Bar Chart depicting the activity of chloramphenicol against 
intracellular B.pseudomallei within J774.1 cells (Triplicate results showing the % 
change in bacterial numbers after 6hrs of incubation). The error bars show the 
standard deviation between the readings obtained for each set of the triplicate. 
Chloramphenicol Killing Assay vs Intracellular 



























Kanamycin 100µg/ml Chloramphenicol 20 µg/ml




At the lowest concentration used, the antibiotic had a bacteriostatic effect on 
intracellular bacterial growth. Higher concentrations of chloramphenicol resulted in the 
killing of intracellular bacteria, though dose-dependency was not observed.  
The killing is approximately equal to that observed against extracellular bacteria, 
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G) Clarithromycin and Erythromcyin 
The results for both these antibiotics are displayed in the Appendix 1.1 (Figures 
A1.5-A1.8 for clarithromycin and Figures A1.9-A1.12 for erythromycin). 
Both these macrolide antibiotics showed very high MIC values and  
displayed poor bactericidal activity, with erythromycin being more effective than 
clarithromycin in both intracellular and extracellular environments. 
 Clarithromycin was shown to be able to achieve high concentrations both 
intracellularly and extracellularly and is often used in the treatment regimens for H.pylori 
(which is able to invade epithelial cells), with eradication rates as high as 90-95% (Hulten 
et al, 1996). However, it appeared that this antibiotic was not able to achieve a similar 
result against B.pseudomallei. 
 As the results showed, B.pseudomallei was confirmed to be highly 
resistant to the bactericidal activity of macrolides. However, it was never the intention to 
use these macrolides as a monotherapy but rather as an adjunct to another antibiotic(s) in 
these studies. Both clarithromycin and azithromycin inhibited the production of alginate 
in biofilm producing bacteria including pseudomonads at sub-MIC levels (Kobayashi et 
al, 1995 and Yasuda et al, 1993). As the biofilm formed by B.pseudomallei was 
implicated as one of the causes for the ability of the bacteria to resist the action of many 
antimicrobials and to persist within the infected host, this ability of the two macrolides 
could be beneficial in the therapy of melioidosis, and perhaps reduce the probability of 
recrudescence. However, as the project had to be terminated prematurely, combinations 
of antibiotics, including that with these macrolides, could not be tested. 
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 It would have been of interest to examine the effect of azithromycin in the 
intracellular assay system. This member of the macrolide family, although similar to the 
other member in terms of spectrum and MIC value, is concentrated within cells to a high 
degree and may show useful activity against B.pseudomallei. Unfortunately, we were 




i) Doxycycline against extracellular B.pseudomallei 
 
Figure 5.19: Graph depicting the activity of doxycycline against extracellular 
B.pseudomallei (Time-course showing the bacterial numbers measured over 24hr). 



















Control Doxycyline 5 µg/ml 10xMIC
Doxycyline 10 µg/ml 20xMIC Doxycyline 20 µg/ml 40xMIC
Doxycyline 50 µg/ml 100xMIC
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Figure 5.20: Bar Chart depicting the activity of doxycycline against extracellular 
B.pseudomallei (Triplicate results showing the % change in bacterial numbers after 
6hrs of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 


























Doxycycline 5µg/m 10xMIC Doxycycline 10µg/ml 20xMIC
Doxycycline 20 µg/ml 40xMIC Doxycycline 50 µg/ml 100xMIC
 
 
Doxycycline was shown to have some ability to kill B.pseudomallei with 
bactericidal activity observed at higher concentrations of 20 and 50μg/ml. At the lower 
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ii) Doxycycline against intracellular B.pseudomallei 
 
Figure 5.21: Graph depicting the activity of doxycycline against intracellular 
B.pseudomallei within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 
 




















Doxycycline 5 µg/ml 10xMIC Doxycycline 10 µg/ml 20xMIC
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Figure 5.22: Bar Chart depicting the activity of doxycycline against intracellular 
B.pseudomallei within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hrs of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. (The graph for 
the kanamycin control was omitted in this case for ease of display) 



























Doxycycline 5µg/ml 10MIC Doxycycline 10µg/ml 20xMIC
Doxycycline 20 µg/ml 40xMIC Doxycycline 50 µg/ml 100xMIC
 
 
As with the extracellular assays, a similar dose-dependent trend was observed in 
the action of doxycycline against intracellular bacteria. At the lower concentrations, the 
antibiotic was bacteriostatic while bactericidal activity was observed at higher levels, 
though the killing was less compared to the same concentration in the extracellular assay. 
 Doxycycline is generally regarded as a bacteriostatic drug in clinical practice. It is 
also known to penetrate cells well. These observations were consistent with the data 
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obtained from our assays. Doxycycline is used clinically as an oral follow-up therapy for 
melioidosis patients. 
 A 0.2g intravenous administration of doxycycline can produce a peak serum level 
of 6.4μg/ml (Lorian, 1996) but the drug was shown to be bacteriostatic at this 
concentration and was only bactericidal at much higher concentrations. However, this 
drug, being an inhibitor of protein synthesis, could perhaps play a role as part of an 
antimicrobial drug combination. 
 
I) Tetracycline 
 The graphs depicting the results for assay of tetracycline against B.pseudomallei 
can be found in the Appendix 1.1 (A1.13-A1.15).  
Tetracycline is known as a bacteriostatic drug and it was indeed shown to be so 
against extracellular B.pseudomallei, with very slow bacterial growth recorded when 10 
μg/ml and 20 μg/ml tetracycline were used. Higher concentrations of tetracycline (50 
μg/ml and 100 μg/ml), however, were bactericidal. 
Tetracycline showed a marked decrease in efficacy when used against 
intracellular B.pseudomallei compared to the case against extracellular B.pseudomallei. 
Even at 50μg/ml, a concentration that was bactericidal in the extracellular assay, the 
antibiotic was bacteriostatic at best.  
The rather high MIC value of 8μg/ml as well as the rather low achievable serum 
concentration (3-4μg/ml when 0.5g was administered orally; from Lorian, 1996) would 
suggest that this antibiotic would not be promising for melioidosis therapy unless it is 
used in combination with another drug. 
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Also, the pH in the phagosome had been linked to the reduction in the bactericidal 
properties of some antibiotics such as tetracycline or doxycycline and this can be 
alleviated by the introduction of alkalinizing lysosomotropic agents such as chloroquine 
or amantadine (Raoult et al, 1990). Although B.pseudomallei is known to escape from the 
phagosome (Harley et al, 1998), an experiment was conducted in which tetracycline and 
chloroquine were introduced concurrently in order to determine if any synergistic effects 
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i) Meropenem against extracellular B.pseudomallei 
 
Figure 5.23: Graph depicting the activity of meropenem against extracellular 
B.pseudomallei (Time-course showing the bacterial numbers measured over 24hr). 
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Figure 5.24: Bar Chart depicting the activity of meropenem against extracellular 
B.pseudomallei (Triplicate results showing the % change in bacterial numbers after 
6hrs of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 
























Meropenem 5 µg/ml 5xMIC Meropenem 10µg/ml 10xMIC
Meropenem 20µg/ml 20xMIC Meropenem 50µg/ml 50xMIC
 
 
Meropenem showed time-dependent killing of B.pseudomallei. There was a slight 
increase in killing observed when higher concentrations were used but with the killing 
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ii) Meropenem against intracellular B.pseudomallei 
 
Figure 5.25: Graph depicting the activity of meropenem against intracellular 
B.pseudomallei within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 



















Control Kanamycin 100 µg/ml
Meropenem 5 µl/ml 5xMIC Meropenem 10 µl/ml 10xMIC
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Figure 5.26: Bar Chart depicting the activity of meropenem against intracellular 
B.pseudomallei within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hrs of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. 






























Kanamycin 100µg/ml Meropenem 5µg/ml 5xMIC
Meropenem 10 µg/ml 10xMIC Meropenem 20µg/ml 20xMIC
Meropenem  50 µg/ml 50xMIC
 
 
Meropenem showed a dose-dependent effect on B.pseudomallei localised within 
the J774.1 host cells but the antibiotic showed lower efficacy when used against 
intracellular B.pseudomallei than against extracellular bacteria.  
Meropenem had been shown to penetrate well into cells, with cellular to 
extracellular concentration ratios of 3-12 having been reported (Cuffini et al, 1993). 
Meropenem had also been shown to be at least as effective as ceftazidime against 
melioidosis in clinical trials conducted by Cheng et al, 2004. Serum concentrations of 
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35.6±5.2μg/ml have been recorded with single intravenous infusions of 500mg 
(Ljungberg et al, 1992). The information sheet provided with the antibiotics, in fact, had 
stated that concentrations above 100μg/ml can be achieved with multiple dosing over a 
period. 
 
K) Piperacillin and Piperacillin-Tazobactam 
 
iA) Piperacillin and Piperacillin-Tazobactam against extracellular 
B.pseudomallei 
 
Figure 5.27: Graph depicting the activity of piperacillin against extracellular 
B.pseudomallei (Time-course showing the bacterial numbers measured over 24hr). 



















Control Piperacillin 20 µg/ml





                                             Studies on Antibiotics Action on Intracellular Bacteria 




Figure 5.28: Bar Chart depicting the activity of piperacillin against extracellular 
B.pseudomallei (Triplicate results showing the % change in bacterial numbers after 
6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 





























Piperacillin 20µg/ml 10xMIC Piperacillin 50µg/ml 25xMIC
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iiA) Piperacillin against intracellular B.pseudomallei 
 
Figure 5.29: Graph depicting the activity of piperacillin against intracellular 
B.pseudomallei within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 

















Control Kanamycin 100 µg/ml
Piperacillin 20 µg/ml 10xMIC Piperacillin 50 µg/ml 25xMIC
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Figure 5.30: Bar Chart depicting the activity of piperacillin against intracellular 
B.pseudomallei within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hrs of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. 




























Kanamycin 100µg/ml Piperacillin 20µg/ml 10xMIC
Piperacillin 50µg/ml 25xMIC Piperacillin 100 µg/ml 50xMIC
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iB) Piperacillin-Tazobactam against extracellular B.pseudomallei 
 
Figure 5.31: Graph depicting the activity of piperacillin plus tazobactam at a ratio 
of 8:1 against extracellular B.pseudomallei (Time-course showing the bacterial 
numbers measured over 24hr). 





















Control Piperacillin 20 µg/ml + Tazobactam 2.5 µg/ml 20xMIC
Piperacillin 50 µg/ml + Tazobactam 6.25 µg/ml 50xMIC Piperacillin 100 µg/ml + Tazobactam 12.5 µg/ml 100xMIC
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Figure 5.32: Bar Chart depicting the activity of piperacillin and tazobactam (8:1) 
against extracellular B.pseudomallei (Triplicate results showing the % change in 
bacterial numbers after 6hrs of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. 

























Piperacillin (20µg/ml) -tazobactam (2.5 µg/ml ) 20xMIC
Piperacillin (50µg/ml) + tazobactam (6.25 µg/ml ) 50xMIC
Piperacillin (100µg/ml) -tazobactam (12.5 µg/ml ) 100xMIC
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iiB) Piperacillin-Tazobactam against intracellular B.pseudomallei 
 
Figure 5.33: Graph depicting the activity of piperacillin plus tazobactam at a ratio 
of 8:1 against intracellular B.pseudomallei within J774.1 cells (Time-course showing 
the bacterial numbers measured over 24hr). 
Piperacillin-tazobactam Killing Assay vs Intracellular 

















Control Kanamycin 100 μg/ml
Piperacillin (20 μg/ml) + Tazobactam (2.5 μg/ml) 20xMIC Piperacillin (50 μg/ml) + Tazobactam (6.25 μg/ml) 50xMIC
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Figure 5.34: Bar Chart depicting the activity of piperacillin and tazobactam (8:1) 
against intracellular B.pseudomallei within J774.1 cells (Triplicate results showing 
the % change in bacterial numbers after 6hrs of incubation). The error bars show 
the standard deviation between the readings obtained for each set of the triplicate. 
 
Piperacillin-tazobactam Killing Assay vs Intracellular 


























Piperacillin (20 µg/ml) + Tazobactam (2.5 µg/ml)  20xMIC
Piperacillin  ( 50µg/ml) + Tazobactam (6.25 µg/ml) 50xMIC
Piperacillin (100 µg/ml ) + Tazobactam (12.5 µg/ml) 100xMIC
Piperacillin (200 µg/ml) + Tazobactam (2.5 µg/ml) 200xMIC
 
Figure 5.27 and 5.28 showed the activity of piperacillin alone against extracellular 
B.pseudomallei while Figures 5.29 and 5.30 show the activity of the same antibiotic when 
used against intracellular B.pseudomallei. 
The action of piperacillin in combination with tazobactam is shown in Figures 
5.31 and 5.32 (against extracellular bacteria) and Figures 5.33 and5.34 showed the killing 
achieved when piperacillin-tazobactam when used against intracellular B.pseudomallei. 
 Comparisons of Figures 5.27 and 5.28 (piperacillin alone) with Figures 5.31 and 
5.32 (piperacillin-tazobactam) shows little difference in the bactericidal activity of 
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piperacillin alone from that of the combination of piperacillin and tazobactam when used 
against  B.pseudomallei in extracellular conditions. 
 Comparing the data from intracellular assays (Figures 5.29 and 5.30 (for 
piperacillin alone) with Figures 5.33 and 5.34), however, shows that piperacillin alone 
was less effective at all concentrations tested than the combination with tazobactam. It is 
possible that intracellular conditions promote the expression of a β-lactamase possessed 
by B.pseudomallei. This model predicts that the combination of piperacillin with 
tazobactam, a broad spectrum inhibitor of β-lactamase, would be more effective than 
piperacillin alone in vivo and testing in an animal model would be useful to verify this. 
The MIC value for piperacillin (1μg/ml) was relatively low compared to that of 
many antibiotics and the antibiotic was able to achieve rather high concentrations in the 
serum (a single 2g intravenous administration can achieve a level of 162-225 μg/ml; 
Lorian, 1996).  As such, this antibiotic is worthy of further studies, particularly given its 
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The results for rifampicin can be found in the Appendix I.1 (Figures A1.17-
A1.20).  
 Against extracellular B.pseudomallei, the drug was observed to be active in a 
dose-dependent manner, being bacteriostatic at the lower concentrations (growth was, in 
fact, observed at the lowest concentration tested) and bactericidal at higher 
concentrations. 
  Rifampicin was known to penetrate cells well and hence was hoped that it would 
be efficacious against intracellular B.pseudomallei. Testing showed that rifampicin, even 
at a rather high concentration of 48μg/ml (6xMIC), was not bactericidal. 44% killing was 
observed at 50xMIC (400μg/ml) but it would be unrealistic to achieve this concentration 
in practice. According to a study done by Vij et al (1995), the peak serum level was only 
10μg/ml when an oral dose of 600mg was applied. This is just over the MIC value of 
8μg/ml. Rifampicin had comparable killing activity against extracellular and intracellular 
bacteria; similar levels were seen at 20 times and 50 times MIC respectively in both 
locations. Although rifampicin is concentrated within cells, its site(s) of accumulation in 
intracellular compartment(s) is still unknown (Carryn et al, 2003). B. pseudomallei 
escapes from the phagosome and is eventually found free in the cytoplasm (Harley et al, 
1998).  Any intracellular concentration of rifampicin may be offset by localisation in 
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Figure 5.35 The Bar chart below depicts the effect of pre-incubation of J774.1 cells 
with a range of IFN-γ concentrations on the survival and growth of intracellular 
B.pseudomallei within these host cells. The cells were pre-incubated with IFN-γ for 
12 hrs prior to infection and the graph below showed the changes in bacterial 
numbers between 0 and 6hr post-infection. 
Effect of pre-incubation with Interferon-gamma on the 













































Prior to infection, J774.1 cells were pre-incubated for 8hr with interferon-gamma 
of concentrations ranging from 100units/ml to 0.0001units/ml in 10-fold dilutions. 
Treatment of J774.1 cells with 100u/ml carried out by McKinney et al (2003) had shown 
that this concentration was not sufficiently high to kill the cells and hence the decreases 
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in bacterial numbers observed here were not due to the cell dying from high doses of 
interferon-γ.  
Preincubation with interferon-gamma up to 1 unit/ml, stimulated bactericidal 
activity directed against B.pseudomallei, resulting in almost 100% clearance in infected 
cells. There was still a reduction in growth within cells treated with interferon-gamma up 
to 0.001unit/ml as compared to the growth observed in untreated cells.  
 It was hoped that cells pre-incubated with IFN-γ could be infected with 
B.pseudomallei and then treated with various antibiotics and antibiotics combinations in 
order to determine if any synergism or antagonism exist. However, as the project had to 
be terminated, further work could not be carried out, including tests for antibiotics 
synergism as well as the fine-tuning of the above antibiotic tests to obtain more data and 
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5.1.4 A Summary of Results and Final Conclusions: (1) Burkholderia pseudomallei 
 Due to the sheer number of results and graphs, a summary of the above results 
follows at this point. 
Several classes of antibiotics were tested against intracellular B.pseudomallei 
using the J774.1 murine macrophage cell line as the host and the results obtained were 
compared against results recorded when the same antibiotics were used against 
extracellular B.pseudomallei.  
 A number of β-lactam antibiotics from several different families were tested. 
Cephalosporins, specifically cephalosporins from Group II (ceftriaxone) and Group III 
(ceftazidime), were tested against intracellular and extracellular B.pseudomallei for their 
efficacy in eliminating the bacteria. Ceftazidime, as had been previously mentioned, 
remains the drug of choice in the treatment of acute melioidosis. The use of ceftriaxone in 
the therapy of melioidosis, however, was not recommended by Chaowagul et al in 1999, 
having showed that, despite good in vitro activity, the use of third generation 
cephalosporins other than ceftazidime had been linked to increased mortality in patients. 
Our results showed that both ceftazidime and ceftriaxone showed good bactericidal 
activity against extracellular B.pseudomallei but their efficacy were greatly reduced when 
used instead against intracellular B.pseudomallei. Both showed comparable killing 
against intracellular bacteria.  Ceftazidime, as mentioned previously, can achieve a serum 
concentration of 105μg/ml, higher than the 50μg/ml tested (which was enough to 
eliminated approximately 20% of the intracellular bacteria). As our work involved only 
in vitro cultured cells and the administration of only a single dosage of the antibiotic over 
24 hours, it would be instructive to proceed on to an animal model experiment, where 
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more physiological conditions could be achieved and the bacterial population could be 
subjected to successive dosages of the antibiotic to determine if complete clearance could 
be achieve after prolonged therapy. In clinical therapy, parenteral treatment using 
ceftazidime is maintained for at least 10 days. Ceftriaxone showed almost comparable in 
vitro activity but its higher MIC value and association with higher mortality reduces the 
drug’s suitability as a candidate for melioidosis treatment. 
 Another β-lactam tested was meropenem, a member of the carbapenem family.  
Carbapenems have been shown to be stable to most β-lactamases and were more rapidly 
bactericidal than most penicillins and cephalosporins due to their ability to bind to 
Penicillin Binding Protein (PBP) -2 as well as PBP-1a and -1b rather than PBP-3 
(Hashizume et al, 1984). Meropenem is increasingly used as a part of melioidosis 
therapy. Our research showed that meropenem was rapidly bactericidal against 
extracellular B.pseudomallei though its effectiveness was dramatically reduced when 
employed against intracellular bacteria. However, sufficient killing against intracellular 
bacteria can be obtained with levels of meropenem shown to be achievable in the serum 
and hence, this drug is promising and should be tested further. 
 Piperacillin was another β-lactam that was tested. This antibiotic showed 
appreciable activity against B.pseudomallei. Among the β-lactams tested, meropenem and 
piperacillin showed the best intracellular activity, with 10xMIC of meropenem achieving 
26% killing at 10xMIC while 10xMIC piperacillin achieved 31%. Ceftazidime at 
10xMIC only resulted in 1.5% killing against intracellular bacteria. Piperacillin has also 
been shown to achieve very high serum concentrations, with a peak serum concentration 
of 162-225μg/ml achievable with a 2g intravenous infusion (Lorian, 1996). In addition, 
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piperacillin in combination with the β-lactamase inhibitor tazobactam is also readily 
available as a commercial preparation Tazocin.  Further discussion on this combination 
can be found below. 
 Β-lactamases are enzymes produced by many bacteria which can hydrolyse β-
lactam antibiotics and render them ineffective against the bacteria. In order to contend 
with the β-lactamases produced by some bacteria, β-lactamase inhibitors, either 
clavulanic acid or penicillanic acid derivatives (eg tazobactam and sulbactam) are used in 
conjunction with certain β-lactam antibiotics. We tested two such combinations, 
amoxicillin-clavulanic acid (Augmentin) and piperacillin-tazobactam (Tazocin).  
Intravenous infusion of amoxycillin-clavulanic acid has been shown to be effective in 
treatment of melioidosis and has been shown to have equivalent clinical response rates to 
ceftazidime (Suputtamongkol et al, 1994b). Intravenous amoxicillin-clavulanic acid 
infusion can be used as an alternative to ceftazidime in clinical therapy (White, 2003). 
We tested this antibiotic and demonstrated that it showed good extracellular killing 
comparable to ceftazidime. In addition, this drug also showed reasonably good 
intracellular penetration although it still showed a marked decline in activity. Piperacillin-
tazobactam has not been clinically tested against B.pseudomallei but the results from our 
in vitro studies showed it to be highly promising as well. The drug combination showed 
good bactericidal activity against extracellular bacteria and also was shown to penetrate 
well into cells. The killing observed using piperacillin-tazobactam was superior to that 
observed when only piperacillin was used.  Many strains of B.pseudomallei possess 
chromosomal inducible β-lactamase enzyme(s) and comparison of the result with 
piperacillin alone versus piperacillin plus tazobactam suggests that the test strain 
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employed did produce such an enzyme during the period of the assay. Therefore, 
piperacillin should be used only in conjunction with a β-lactamase inhibitor in order to 
avoid the possibility of treatment failures in clinical cases caused by inducible 
piperacillin resistance. 
 Two macrolide antibiotics were also tested. Macrolides are generally recognised 
as bacteriostatic drugs though they are bactericidal against certain species of bacteria. 
The choice of macrolides were in part due to the reports that these antibiotics play a role 
in the inhibition of biofilm production (Kobayashi et al, 1995 and Yasuda et al, 1993) 
and it was hoped to test these macrolides in combination with other antibiotics. We tested 
clarithromycin and erythromycin against extracellular and intracellular B.pseudomallei. It 
would have been instructive to also include azithromycin in our research due to its 
superior cellular penetration and high concentration but unfortunately we were unable to 
procure the drug as the local distributors do not stock this antibiotic in pure or IV form. 
As expected, both erythromycin and clarithromycin performed poorly as a 
monotherapeutic agent. Unfortunately, the project was terminated before we could 
proceed beyond the preliminary stage and hence no combination studies could be carried 
out. 
 Chloramphenicol and two of the tetracycline family, tetracycline and doxycycline, 
were also tested. These drugs are generally recognised as bacteriostatic drugs and that 
agreed with our observations when lower concentrations were used. When used at 
sufficiently high concentrations, the drugs showed some bactericidal activity. Of these 
drugs, doxycycline showed the best activity against B.pseudomallei and had the lower 
MIC value. Doxycycline is currently used as an oral follow-up drug for melioidosis 
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patients. Further studies involving doxycycline could be informative and the drug, being 
a protein synthesis inhibitor, could be useful as part of a combination therapy. 
 Rifampicin, a member of the class of rifamycins, is known to have good cellular 
penetration qualities and we have shown in our assays that this is also true for J774.1 
cells. However, the relatively poor bactericidal activity against B.pseudomallei, coupled 
with the high MIC (and low peak serum level) meant that this drug is unlikely to be 
useful in melioidosis therapy. 
 The fluoroquinolone ciprofloxacin exhibited very good bactericidal activity 
against B.pseudomallei. At 5xMIC, approximately 80% killing was observed against both 
extracellular and intracellular B.pseudomallei. This showed that ciprofloxacin was not 
only highly and rapidly bactericidal but also able to penetrate cells easily with little, if 
any, loss in efficacy. It had also been shown that ciprofloxacin, in combination with 
either clarithromycin or azithromycin, was bactericidal to Pseudomonas aeruginosa 
(Kobayashi et al, 1993) and hence it was hoped that this combination could have been 
tested during the course of this project. However, the use of ciprofloxacin in clinical 
therapy may be complicated by the low peak serum level that can be achieved. An 
intravenous dose of 400mg produced only a serum level of 4μg/ml (i.e., only 4xMIC). 
Also, ciprofloxacin had been tested in animal studies and shown to be effective in the role 
of prophylaxis against B.pseudomallei but was not effective therapeutically (Russel et al, 
2000). In a clinical study conducted by Chetchotisakd et al (2001a), ciprofloxacin was 
prescribed in combination with azithromycin as an oral follow-up therapy for 
melioidosis.  The results showed that this combination failed to perform as well as other 
regimens tested. 
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 In summary, among all the drugs tested, ceftazidime, meropenem, ciprofloxacin, 
amoxicillin-clavulanic acid and piperacillin-tazobactam showed the most promise in the 
role as agents against intracellular B.pseudomallei. In general, every drug (except 
ciprofloxacin and rifampicin) showed some lessening in activity when targeting 
intracellular bacteria compared to against extracellular bacteria. The degree of reduction 
on efficacy varied from drug to drug with some, such as amoxicillin-clavulanic acid and 
piperacillin-tazobactam and piperacillin alone showing a relatively lower reduction in 
activity against intracellular bacteria. Ceftazidime and meropenem, while both showing 
reduced effectiveness, could still achieve some killing and could still be able to eliminate 
the intracellular bacteria after sufficiently long course of treatment. 
These are results obtained for in vitro assays and are far from comprehensive. Some 
drugs like ciprofloxacin had been shown to be effective in vitro but successes in clinical 
therapy had been limited. Therefore, further work should be carried out on this (see future 
directions) 
 Our preliminary work with murine interferon-gamma had shown that pre-
incubation with IFN-γ greatly induces the bactericidal activity of the J774.1 cells. This 
was also described by Miyagi et al in 1997. It was hoped that antibiotics could be tested 
in combination with IFN-γ in order to determine if the interactions, if any, between the 
antibiotics and the nascent antimicrobial mechanisms of the cell that had been stimulated 
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5.2 Salmonella Typhimurium 
  
 5.2.1 Acridine Orange Staining of Infected J774.1 Cells 
 J774.1 cells were infected with Salmonella Typhimurium and stained with 
acridine orange and crystal violet before being viewed under a UV fluorescence 
microscope. This is to show that Salmonella Typhimurium do indeed enter the J774.1 
cells. The addition of the crystal violet stain quenches the fluorescence of the bacteria and 
only bacteria found within the confines of the cell membrane would still fluoresce when 
the sample was subsequently viewed under UV light.  
 
Figure 5.36: Pictures taken of infected J774.1 cells stained with acridine orange and 
quenched with crystal violet. The Salmonella Typhimurium bacteria show up as 
green fluorescent rods. Extracellular bacteria do not fluoresce as crystal violet 
quenches this effect in this location (Taken at 1000x Magnification)  
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Figure 5.36: Pictures taken of infected J774.1 cells stained with acridine orange and 
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5.2.2 Minimum Inhibitory Concentrations 
 Table  5.2: Chart listing the MIC values obtained for the antibiotics used in assays 
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5.2.3 Antibiotics Killing Assays 
  
Note: In order to ensure reproducibility of the data obtained, each of these assays 
shown below had been performed thrice. The data exhibited in this section are each 
a representative set out of 3 sets of results from similar assays.  An additional set of 




Figure 5.37: Graph depicting the activity of gentamicin against extracellular 
Salmonella Typhimurium (Time-course showing the bacterial numbers measured 
over 24hr). 




















Extracellular Control(no gentamicin) Extracellular Gentamicin 100µg/ml
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 Gentamicin at 100μg/ml was rapidly lethal to S.Typhimurium and eliminated all 
the bacteria within 2hr.  
 
Figure 5.38: Graph depicting the activity of gentamicin against intracellular 
Salmonella Typhimurium within J774.1 cells (Time-course showing the bacterial 
numbers measured over 24hr). 
 




















Control(no gentamicin) Gentamicin 25µg/ml Gentamicin 100µg/ml
 
 Gentamicin penetrates J774.1 poorly and the S.Typhimurium present within the 
cells was protected from the gentamicin. However, at 100μg/ml, there appeared to be a 
slow leak of gentamicin into the cells and by 24hr, a decline in the bacteria numbers 
could be observed.  
 A search through the literature shows that gentamicin is commonly used to 
eliminate any extracellular bacteria to produce a system in which the only surviving 
bacteria were located within the protection of the host cells. Gentamicin was well suited 
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for this role as it was able to kill any extracellular bacteria rapidly yet penetrate 
eukaryotic cells poorly.  
 As with the work done with B.pseudomallei in the previous section, two sets of 
controls were used in the intracellular assay system, an antibiotic-free control and a 
second control in which an aminoglycoside antibiotic (gentamicin in this case) was used 
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B) Ceftriaxone and Cefotaxime 
 
Ceftriaxone and cefotaxime showed similar trends against S.Typhimurium.  As  
such, only the results for assays using ceftriaxone were presented here. The results for 
cefotaxime can be found in the Appendix 1.2 (Figures A1.21-A1.24). 
 
i) Ceftriaxone against extracellular Salmonella Typhimurium 
 
Figure 5.39: Graph depicting the activity of ceftriaxone against extracellular 
Salmonella Typhimurium (Time-course showing the bacterial numbers measured 
over 24hr). 



















Control Ceftriaxone 1xMIC (0.5µg/ml) Ceftriaxone 10xMIC (5µg/ml)
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Figure 5.40: Bar Chart depicting the activity of ceftriaxone against extracellular 
Salmonella Typhimurium (Triplicate results showing the % change in bacterial 
numbers after 6hrs of incubation). The error bars show the standard deviation 
between the readings obtained for each set of the triplicate. 
























Ceftriaxone  1xMIC (0.5 µg/ml) Ceftriaxone  10xMIC (5 µg/ml)
Ceftriaxone  50xMIC (25 µg/ml) Ceftriaxone  100xMIC 50 µg/ml)  
 
Both cefotaxime and ceftriaxone were rapidly bactericidal against extracellular 
Salmonella Typhimurium, with almost 100% killing recorded even at 1xMIC.   The 
killing was dose-dependent, with complete clearance of the bacteria observed at earlier 
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ii) Ceftriaxone against intracellular Salmonella Typhimurium 
 
Figure 5.41: Graph depicting the activity of ceftriaxone against intracellular 
Salmonella Typhimurium within J774.1 cells (Time-course showing the bacterial 
numbers measured over 24hr). 






















Ceftriaxone Killing Assay vs cellular S.Typhimuri m 
within .1 
Control Gentamicin 100µg/ml
Ceftriaxone 1xMIC (0.5µg/ml) Ceftriaxone 10xMIC (5µg/ml)
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Figure 5.42: Bar Chart depicting the activity of ceftriaxone against intracellular 
Salmonella Typhimurium within J774.1 cells (Triplicate results showing the % 
change in bacterial numbers after 6hrs of incubation). The error bars show the 
standard deviation between the readings obtained for each set of the triplicate. 




























Gentamicin 100 µg/ml Ceftriaxone  1xMIC (0.5 µg/ml)
Ceftriaxone  10xMIC (5 µg/ml) Ceftriaxone  50xMIC (25 µg/ml)
Ceftriaxone  100xMIC (50 µg/ml)  
 
   Against intracellular S.Typhimurium, both cefotaxime and ceftriaxone showed 
apparently poor penetration into the J774.1 cells. At concentrations of 1xMIC and 
10xMIC, no net killing was recorded. At 1xMIC, bacterial growth was observed at a rate 
comparable with the gentamicin control. At 10xMIC, bacterial growth occurred at a rate 
much lower than the gentamicin control but increase in bacteria numbers were still 
observed. Bactericidal activity was observed at higher concentration though dose 
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dependency was not observed after 6hr (but dose-dependent killing was more apparent 
after 24hr). 
 Comparing the results for cefotaxime and ceftriaxone, it could be seen that both β-
lactams showed very efficient killing against S.Typhimurium when used against the 
bacteria extracellularly. Against intracellular S.Typhimurium, both cefotaxime and 
ceftriaxone showed dramatically reduced efficacy. At 1xMIC, there were no killings 
observed in any of the experiments.  
These results agree with that reported by Chiu et al (1999), which evaluated the 
activity of several antibiotics including ceftriaxone, though not cefotaxime. It was 
reported that ceftriaxone showed poor killing when S.Typhimurium or S.Enteritidis was 
sequestered within the host cells (P388D1 was used) and that, at best, bacteriostatic 
activity was observed even at 10xMIC. This suggested that both β-lactams penetrated 
eukaryotic cells poorly and would not be effective in the clearance of intracellular 
pathogens which are able to survive within the host cells unless very high concentrations 
were used. However, both cefotaxime and ceftriaxone can, in fact, achieve high peak 
serum concentrations in therapeutic doses. An administration of 1g intravenous dosage of 
cefotaxime can produce a peak serum concentration of 100μg/ml while ceftriaxone can 
achieve the peak serum level of 100-175μg/ml when an intravenous dosage of 1g was 
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i) Ciprofloxacin against extracellular Salmonella Typhimurium 
 
Figure 5.43: Graph depicting the activity of ciprofloxacin against extracellular 
Salmonella Typhimurium (Time-course showing the bacterial numbers measured 
over 24hr). 
 




















Control Ciprofloxacin 1xMIC (0.125µg/ml)
Ciprofloxacin 10xMIC (1.25µg/ml) Ciprofloxacin 20xMIC (2.5µg/ml)
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Figure 5.44: Bar Chart depicting the activity of ciprofloxacin against extracellular 
Salmonella Typhimurium (Triplicate results showing the % change in bacterial 
numbers after 6hrs of incubation). The error bars show the standard deviation 
between the readings obtained for each set of the triplicate. 
























Ciprofloxacin  1xMIC (0.125 µg/ml) Ciprofloxacin  10xMIC (1.25 µg/ml)
Ciprofloxacin  20xMIC (2.5 µg/ml) Ciprofloxacin  50xMIC (6.25 µg/ml)
Ciprofloxacin Killing A say vs Intrace lular S.Typhimurium 
w  J 74.1 
 
Ciprofloxacin was rapidly lethal against S.Typhimurium in an extracellular 
environment. Almost 100% killing was observed even at 1xMIC concentration and the 
killing was dose-dependent, as can be seen in the time kill curve where the higher 
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ii) Ciprofloxacin against intracellular Salmonella Typhimurium 
 
Figure 5.45: Graph depicting the activity of ciprofloxacin against intracellular 
Salmonella Typhimurium within J774.1 cells (Time-course showing the bacterial 
numbers measured over 24hr). 





















Ciprofloxacin 1xMIC (0.125µg/ml) Ciprofloxacin 10xMIC (1.25µg/ml)
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Figure 5.46: Bar Chart depicting the activity of ciprofloxacin against intracellular 
Salmonella Typhimurium within J774.1 cells (Triplicate results showing the % 
change in bacterial numbers after 6hrs of incubation). The error bars show the 
standard deviation between the readings obtained for each set of the triplicate. 






























Gentamycin 100 µg/ml Ciprofloxacin  1xMIC (0.125 µg/ml) Ciprofloxacin  10xMIC (1.25 µg/ml)
Ciprofloxacin  20xMIC (2.5 µg/ml) Ciprofloxacin  50xMIC (6.25 µg/ml)




When the bacteria were sequestered within J774.1 cells, the rate of killing was 
significantly reduced. 1xMIC ciprofloxacin, able to eliminate nearly 100% of the 
extracellular bacteria, was only bacteriostatic at best against intracellular salmonellae. 
However, concentrations of ciprofloxacin of 10xMIC and above were able to eliminate 
almost all the bacteria present.  
Ciprofloxacin, with its low MIC value of 0.125μg/ml, showed much promise as a 
possible drug of choice to completely clear a Salmonella Typhimurium infection. With 
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the ability to achieve a serum concentration of 1.9-2.9μg/ml with an oral dose of 0.5mg, 
this drug could be potentially useful in clearing S.Typhimurium infection from the host, 
even from within infected cells.  
However, ciprofloxacin, as well as other quinolones, are not commonly 
prescribed for children. This was due to the observations in several studies that linked the 
use of this class of antibiotics to arthropathy in young animals (Burkhardt et al, 1997, and 
Warren, 1997).  However, this was not shown to occur in adult animals (Burstein et al, 
2002) and hence ciprofloxacin can be safely used for adults (above the age of 18 years). 
 
D) Chloramphenicol 
The data for chloramphenicol can be found in the Appendix 1.2 (Figures A1.25-
A1.28).  
 When directed against extracellular S.Typhimurium, chloramphenicol at 1xMIC 
was a bacteriostatic drug as expected, but at higher concentrations of 10xMIC and above, 
chloramphenicol showed a dose-dependent bactericidal against S.Typhimurium.  
 Chloramphenicol showed poor cell penetration, with intracellular bacteria growth 
observed at concentrations up to 10xMIC. At the highest concentration tested 
(200xMIC), approximately 40-45% killing was recorded. 
 Chloramphenicol acts by inhibiting protein synthesis and is commonly recognised 
as a bacteriostatic drug, although high levels may be bactericidal against certain bacteria 
as was shown here. The high MIC value (16μg/ml) of this antibiotic and the fact that 
significant intracellular killing was only observed at 20xMIC (320μg/ml), where less than 
10% killing was observed in most cases, meant that this antibiotic would be a poor choice 
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for the role of completely eliminating the intracellular S.Typhimurium. This is especially 
so considering the peak serum level that was achieved was only 4.9-12μg/ml when 1g 
was administered intravenously. However, this antibiotic was chosen not mainly for the 
role as a possible monotherapy but also for possible synergy with other drugs. It was 
hoped that the protein synthesis inhibiting action of chloramphenicol could increase the 
efficacy of other antibiotics, perhaps by blocking the production of enzymes with roles in 
antibiotic resistance like β-lactamases or efflux-pump proteins or perhaps by blocking the 
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i) Meropenem against extracellular Salmonella Typhimurium 
 
Figure 5.47: Graph depicting the activity of meropenem against extracellular 
Salmonella Typhimurium (Time-course showing the bacterial numbers measured 
over 24hr). 




















Control Meropenem 1xMIC (0.5µg/ml)
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Figure 5.48: Bar Chart depicting the activity of meropenem against extracellular 
Salmonella Typhimurium (Triplicate results showing the % change in bacterial 
numbers after 6hrs of incubation). The error bars show the standard deviation 
between the readings obtained for each set of the triplicate. (The error bars in the 
chart below are too small and hence not visible) 























Meropenem  1xMIC (0.5 µg/ml) Meropenem  10xMIC (5 µg/ml)
Meropenem  50xMIC (25 µg/ml) Meropenem  100xMIC (50 µg/ml)  
 
Meropenem was rapidly bactericidal against extracellular S.Typhimurium, with 
almost 100% killing of extracellular bacteria recorded even at 1xMIC. The killing 
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ii) Meropenem against intracellular Salmonella Typhimurium 
 
Figure 5.49: Graph depicting the activity of meropenem against intracellular 
Salmonella Typhimurium within J774.1 cells (Time-course showing the bacterial 
numbers measured over 24hr). Gentamicin, like other aminoglycosides, penetrates 
human cells slowly, taking several days to reach maximum intracellular 
concentration (Carryn et al, 2003). We showed in our model that by 24 hours, 
significant killing of S.Typhimurium had occurred at 100 μg/ml (Figure 5.38, page 
102). Therefore we focused on results obtained in the earlier periods (2-4 hours 
exposure to antibiotics) throughout this thesis when using gentamicin controls to 
define true intracellular viable bacterial counts. 





















Meropenem 1xMIC (0.5µg/ml) Meropenem 10xMIC (5µg/ml)





                                             Studies on Antibiotics Action on Intracellular Bacteria 




Figure 5.50: Bar Chart depicting the activity of meropenem against intracellular 
Salmonella Typhimurium within J774.1 cells (Triplicate results showing the % 
change in bacterial numbers after 6hrs of incubation). The error bars show the 
standard deviation between the readings obtained for each set of the triplicate. 


























Gentamicin 100 µg/ml Meropenem  1xMIC (0.5 µg/ml)
Meropenem  10xMIC (5 µg/ml) Meropenem  50xMIC (25 µg/ml)
Meropenem  100xMIC (5µg/ml)




Paradoxically, meropenem was extremely poor against intracellular 
S.Typhimurium. Even at 50xMIC, bacterial growth was still recorded within the J774.1 
cells, though a small decrease in bacterial numbers was noted at 100xMIC. With 
increasing concentration of meropenem, the rates of increase of bacterial numbers were 
reduced but killing was only observed at 100xMIC.   
In experiments involving B.pseudomallei, meropenem had shown a marked 
decrease in activity but still showed some intracellular killing. However, the antibiotic 
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appeared far less efficacious against intracellular S.Typhimurium, with killing only 
observed at 100xMIC (50μg/ml) and even at this concentration, the results varied, with 
some experiments showing very low rate of killing and others showing no killing at all. 
Unlike B.pseudomallei which escapes the phagosomes and enters the cytoplasm (Harley 
et al, 1998), S.Typhimurium remains within the phagosome and survives by inhibiting 
the fusion of the phagosome with the lysosomes (Hashim et al, 2000).  It would suggest 
that the survival of S.Typhimurium within this cellular compartment conferred the 
bacteria protection from the action of meropenem, which was ineffective either due to the 
inability to enter the phagosome or perhaps due to unsuitable conditions (eg, low pH) 
within the phagosome. 
As such, this antibiotic, while very effective in killing extracellular 
S.Typhimurium, would be unsuitable as a monotherapy as the antibiotic showed very 
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i) Rifampicin against extracellular Salmonella Typhimurium 
 
Figure 5.51: Graph depicting the activity of rifampicin against extracellular 
Salmonella Typhimurium (Time-course showing the bacterial numbers measured 
over 24hr). 




















Control Rifampicin 1xMIC (16µg/ml)
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Figure 5.52: Bar Chart depicting the activity of rifampicin against extracellular 
Salmonella Typhimurium (Triplicate results showing the % change in bacterial 
numbers after 6hr of incubation). The error bars show the standard deviation 
between the readings obtained for each set of the triplicate. (Note: the error bars 
were too small to be visible in this chart) 
 
 























Rifampicin  1xMIC (16 µg/ml) Rifampicin  10xMIC (160 µg/ml)
Rifampicin  20xMIC (320 µg/ml) Rifampicin  30xMIC (480 µg/ml)  
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ii) Rifampicin against intracellular Salmonella Typhimurium 
 
Figure 5.53: Graph depicting the activity of rifampicin against intracellular 
Salmonella Typhimurium within J774.1 cells (Time-course showing the bacterial 
numbers measured over 24hr). 




















Rifampicin 1xMIC (16µg/ml) Rifampicin 10xMIC (160µg/ml)
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Figure 5.54: Bar Chart depicting the activity of rifampicin against intracellular 
Salmonella Typhimurium within J774.1 cells (Triplicate results showing the % 
change in bacterial numbers after 6hr of incubation). The error bars show the 
standard deviation between the readings obtained for each set of the triplicate. 
 




























Gentamicin 100 µg/ml Rifampicin  1xMIC (16 µg/ml) Rifampicin  10xMIC (160 µg/ml)
Rifampicin  20xMIC (320 µg/ml) Rifampicin  30xMIC (480 µg/ml)  
 
 Rifampicin, at 1xMIC, was able to knock down the numbers of intracellular 
S.Typhimurium by nearly 2-log scales. The killing observed was time- and dose-
dependent and the drug showed good intracellular penetration, with only a slight decline 
in killing compared to the killing observed against extracellular bacteria. 
 However, the drug’s effectiveness was offset by the high MIC value of 16μg/ml. 
It was shown that for an oral dose of 600mg, the peak serum level was only 10μg/ml (Vij 
et al, 1995). Rifampicin was also known to reduce the efficacy of many other drugs and 
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so usage of this drug must be planned carefully. This antibiotic was chosen as it was 
known to be able to penetrate cells well and could possibly be useful as a drug of last 
resort as a dosage high enough to achieve 16μg/ml (the MIC value) in the patient’s serum 
could potentially eliminate close to 80% of the intracellular bacteria and almost all the 
extracellular bacteria. A continuous course of rifampicin could potentially clear the 
infection, even from the infected cells. Of course, these results were in vitro and efficacy 
must be tested within an animal model to confirm this. Also, resistance must also be a 
concern as the drug would be rendered useless if resistance commonly arose. Resistance 
to rifamycins occur easily by a one-step mutation in all bacteria examined, and this can 
be observed during therapy of various infections (O’Grady et al, 1997). Rifampicin is not 
presently used in the treatment of salmonella infections so reporting of resistance in 
antibiotics surveillance exercises is not commonly done. However, Sentilkumar et al 
(2005) recently reported that 4 out of the 6 chronic S.Typhi carriers examined had 
rifampicin resistant strains. 
 
G) Tetracycline 
The results for tetracycline are presented in the Appendix 1.2 (Figures A1.29-
A1.32). 
Tetracycline was shown to be bactericidal against extracellular  
S.Typhimurium when used at higher concentrations. At 1xMIC, tetracycline was 
bacteriostatic or slightly bactericidal (the result varied slightly between experiments). At 
10xMIC and above, tetracycline was clearly bactericidal, with killing of 100% observed 
in test samples with 20xMIC and 30xMIC concentrations of tetracycline.  
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 Against S.Typhimurium localised within J774.1, a low level growth in bacterial 
numbers could be observed. Tetracycline introduced at 10xMIC was slightly bactericidal, 
with around 10% killing recorded. Higher rates of bacterial killing were observed with 
increasing tetracycline concentration, with almost complete elimination observed at 
30xMIC. 
 Tetracycline binds to the 30s ribosome and hence blocks protein production. It, 
like chloramphenicol, was generally recognised as bacteriostatic drugs. At 1xMIC, killing 
of 26% was recorded against extracellular bacteria but the efficacy was much reduced 
when the bacteria were located within the host cells. Slight growth was observed 
although the growth rate was consistently below that observed for chloramphenicol, 
hence showing that tetracycline was slightly more effective against S.Typhimurium. 
Killing was observed when higher concentrations were used, peaking at 90% for 
30xMIC. However, the peak serum level of tetracycline in human serum is low (3-4μg/ml 
with an oral dose of 0.5g) and with the high MIC value, it is not expected that this 
antibiotic would be clinically useful as a monotherapy but like chloramphenicol, it was 
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5.2.4 Effect of Antibiotics against S.Typhimurium within THP-1 Human Monocytic 
Cell Line 
 
Figure 5.55: A comparison between the efficacy of ciprofloxacin against 
intracellular S.Typhimurium in J7774.1 and in THP-1 cells 


























Gentamycin 100 µg/ml Ciprofloxacin  1xMIC (0.125 µg/ml)
Ciprofloxacin  10xMIC (1.25 µg/ml) Ciprofloxacin  20xMIC (2.5 µg/ml)
Ciprofloxacin  50xMIC (6.25 µg/ml)  






























Gentamicin 100µg/ml Ciprofloxacin 1xMIC (0.125µg/ml)
Ciprofloxacin 10xMIC (1.25µg/ml) Ciprofloxacin 20xMIC (2.5µg/ml)
Ciprofloxacin 50xMIC (6.25µg/ml)  
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 The antibiotics ceftriaxone, cefotaxime, ciprofloxacin, meropenem, rifampicin 
and tetracycline were also tested for their efficacy against S.Typhimurium when a human 
monocytic cell line, THP-1, was used instead of the murine cell-line J774.1. 
 The differences in the efficacy of these antibiotics against S.Typhimurium found 
in either J774.1 cells or THP-1 cells were minimal and can be considered due to 
biological variations, hence suggesting that the ability of these antibiotics to penetrate the 
mouse cell line and the human cell line were similar and hence, the results obtained using 
J774.1 could likely predict the situation when actual human cells were infected with 
S.Typhimurium. J774.1 was chosen as it is a popular cell line used as a model for 
intracellular infections in many published papers. As we had later managed to secure a 
stock of THP-1 courtesy of Dr. Seah Geok Teng, Department of Microbiology, NUS, it 
was decided that a comparison of the antibiotics action against S.Typhimurium infecting 
both cell lines could be informative.  
Each assay was performed twice and one set of results is included. In this 
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5.2.5 Antibiotics Combinations 
 
 The combinations of antibiotics listed in the table below were tested against both 
intracellular and extracellular S.Typhimurium for any synergy or antagonism. For each 
combination, the assays had been performed in triplicate on three separate occasions to 
ensure reproducibility. The % changes in bacteria numbers after 6 hours of incubation 
with the antibiotic combination was recorded and the data from all three separate assays 
were averaged and presented in Appendix 1.4 (Table A1.1 and Table A1.2). Table A1.1 
shows the results for the extracellular assays while Table A1.2 shows the results when the 
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Table 5.3: Table listing the conclusions from antibiotic combinations tested against 
Salmonella Typhimurium:  intracellularly and extracellular assays. Observations 
were similar for both intracellular and extracellular assays unless specified. 
Antibiotics Combination Observations 
Ciprofloxacin + 
Ceftriaxone 
No effect observed  
Ciprofloxacin + 
Rifampicin 




No net effect observed 
Rifampicin + 
Ceftriaxone 
No net effect observed 
Tetracycline + 
Rifampicin 
No net effect observed  
Tetracycline + 
Chloramphenicol 
Very slight synergism in killing observed both 
intracellularly and extracellularly 
Ciprofloxacin + 
Chloramphenicol 
Very slight antagonism was observed 
Ciprofloxacin + 
Tetracycline 
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Table 5.3 (continued): Table listing the conclusions from antibiotic combinations 
tested against Salmonella Typhimurium both intracellularly and extracellularly. 
Antibiotics Combination Observations 
Ceftriaxone + 
Chloramphenicol 
Extracellular: Clear antagonism was observed when 
low concentration of chloramphenicol (1xMIC) was 
used with ceftriaxone. However, when 10xMIC 










Cro1 Chl1 Cro1xChl1 
-99.95 +8.62 -25.47 
Cro1 Chl10 Cro1xChl10 
-99.95 -85.81 -96.37 
 
 
Intracellular: No net effect was observed.  
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Table 5.3 (continued): Table listing the conclusions from antibiotic combinations 
tested against Salmonella Typhimurium both intracellularly and extracellularly 
Tetracycline + 
Ceftriaxone 
Extracellular: Clear antagonism was observed when a 
low concentration of tetracycline (1xMIC) was used in 









Tet1 Cro1 Tet1xCro1 
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Table 5.3 (continued): Table listing the conclusions from antibiotic combinations 
tested against Salmonella Typhimurium both intracellularly and extracellularly. 





Intracellular: antagonism observed when 10xMIC 












Tet1 Cro1 Tet1xCro1 
+23.65 +6.80 +20.59 
Tet1 Cro10 Tet1xCro10 
+23.65 -55.72 -7.18 
 
 
Antagonism was observed when chloramphenicol was used with ceftriaxone 
against extracellular S.Typhimurium. Slight antagonism was also observed when 
chloramphenicol was used with ciprofloxacin. On theoretical grounds, it has been 
predicted that a bacteriostatic drug will antagonise the action of a second bactericidal 
agent, as the latter typically only kills actively dividing bacteria (Eliopoulus GM and 
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Moellering RC; Chapter 9 in Lorian, 1996). As chloramphenicol was shown to be 
bactericidal in higher concentrations, this may alleviate the inhibitory effect and explain 
why inhibition was observed to be lower or non-existent when chloramphenicol 10xMIC 
was combined with these antibiotics. Ciprofloxacin had been shown to work 
antagonistically with chloramphenicol against Escherichia coli (Neu, 1989).  Antagonism 
between chloramphenicol and ceftriaxone or cefotaxime had also been observed 
previously when the combinations were tested against isolates of various bacteria 
including Escherichia coli, Staphylococcus aureus and 5 isolates of Salmonella species 
(but not S.Typhimurium) (Asmar et al, 1988). A study by Jadavji et al (1984) showed that 
no synergism or antagonism was observed between rifampicin and chloramphenicol 
when used against Haemophilus influenzae and our observations with S.Typhimurium 
agreed with this finding.  
Tetracycline, another bacteriostatic drug, showed a similar trend as that shown by 
chloramphenicol with the exception that tetracycline and ceftriaxone was shown to be 
antagonistic even against intracellular S.Typhimurium. The lack of antagonism when 
1xMIC of both antibiotics were combined could be due to the poor penetration of 
ceftriaxone and the intracellular concentration of ceftriaxone was too low to have any 
effect. 
The combination or tetracycline and chloramphenicol was shown to be slightly 
synergistic both in intracellular and extracellular conditions. Tetracycline interferes with 
the protein synthesis mechanism by binding to the 30s ribosome while chloramphenicol 
binds to the 50s subunit. It is possible that the binding of these two antibiotics to their 
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target site could more efficiently block protein synthesis and hence their effect was 
synergistic. 
Michelet et al (1997), tested several fluoroquinolones in combination with 
rifampicin against intracellular Listeria monocytogenes and reported a strong indication 
of antagonism between rifampicin and the fluoroquinolones tested (clinafloxacin, 
levofloxacin, ofloxacin, and sparfloxacin), though ciprofloxacin was not among the 
fluoroquinolones tested. In our experiments, no antagonism was observed between 
ciprofloxacin (or ceftriaxone) when used in tandem with rifampicin, which is a 
bactericidal drug.  
 Given time, more in-depth tests could be carried out to confirm the results and 
also to examine the sub-MIC concentrations of the drugs to determine if any sub-MIC 
effect could be elucidated. Sub-MIC concentrations of these antibiotics could also be 
combined to test if any synergy or antagonism could be observed. This may be a more 
sensitive determinant as some of the antibiotics tested were rapidly bactericidal and the 
rapid killing may mask any small additive effects.  Currently, the lowest concentration 
used was 1xMIC and some antibiotics, even at this concentration were capable of killing 
almost all the bacteria present when used extracellularly. Hence the sensitivity of the 
extracellular combination assays may be lower. However, as the main aim of this project 
was to determine intracellular activity, it was decided to leave out the sub-MIC assays 
unless time permits. Unfortunately, due to the lack of time, sub-MIC combinations could 
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5.2.6 Effect of Interferon-gamma on the Survival of Intracellular S.Typhimurium in 
J774.1 and Its Use in Tandem with Selected Antibiotics 
 The data for these assays can be found in Appendix 1.5 (A1.40-A1.46). 
Comparing between the cells pre-incubated with IFN-γ and the control cells that were 
incubated with only 0.5% BSA in PBS (the diluent for the IFN-γ), it was observed that 
the number of bacteria found in the cells pre-incubated with IFN-γ was generally lower at 
6 hours post-infection compared to the bacterial count at the start. The effect of IFN-γ on 
the J774.1 cells was found to be variable and different killing rates were observed in 
different assays. On several occasions, pre-stimulation with IFN-γ kept the numbers of 
intracellular bacteria static but no net killing was observed. The bacterial count after 6 
hours in the control cells are always higher than at the starting point.  
  Antibiotics were then tested against S.Typhimurium infecting these pre-activated 
cells in order to determine if any additive or synergistic killing could be observed.  Each 
assay was performed thrice and two sets of results are included in this dissertation, one in 
Appendix 1 and another in Appendix 2. 
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In general, no synergistic activities were observed for any of the antibiotics tested. 
It could be seen in the tests that there were occasionally slight increases in the killing 
when the antibiotics were used alongside pre-incubation with IFN-γ but these differences 
were not statistically significant. None of the antibiotics tested showed a clear difference 
in bactericidal activity when used against S.Typhimurium infecting the IFN-γ activated 
cells as compared to when used against the bacteria in unstimulated cells. 
 While no antibiotics were observed to act synergistically with IFN-γ pre-
stimulation, meropenem was observed to antagonise the bactericidal activity of the pre-
stimulated cells. It was found that the bacterial killing observed in pre-stimulated J774.1 
cells were lower when meropenem was introduced into the system as compared to the 
killing observed in infected pre-stimulated cells without the addition of meropenem. 
When used in tandem with pre-activation of the cells by IFN-γ, the antibiotic actually 
appeared to reduce the efficacy of the cells’ killing mechanism as the killing observed 
was actually lower compared to non pre-activated cells and meropenem. This could be 
due to the suppressive effect of the antibiotic on some of the bactericidal mechanisms 
stimulated by IFN-γ: for example, the antibiotic may affect the pH of the phagosomes 
inside which the bacteria exist or by modifying the cell wall to render it less susceptible 
to phagosomal killing mechanisms. However, no previous description of this 
phenomenon has been described in the literatures and there is insufficient information 
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5.2.7 Summary of Results and Final Conclusions: (2) Salmonella Typhimurium 
 As was observed in the work performed on melioidosis, cephalosporins such as 
ceftriaxone and cefotaxime once again exhibited a significant reduction in bactericidal 
activity when used against intracellular S.Typhimurium in comparison to their activities 
against extracellular bacteria.  Although both antibiotics showed very good bactericidal 
activity when used against extracellular salmonellae, bacteria killing were markedly 
reduced when the bacteria was protected within the host cells. 
 The other β-lactam antibiotic tested was meropenem. This carbapenem had been 
shown to have reduced efficacy when used against intracellular B.pseudomallei but 
killing was still observed. However, when used against intracellular S.Typhimurium, the 
antibiotic exhibited a drastic reduction in bactericidal activity. Against extracellular 
salmonellae, the antibiotic, even at 1xMIC, completely eliminated the bacteria within 6 
hours of incubation. However, when directed against intracellular salmonellae, 
intracellular bacterial growth was observed even when 50xMIC was used. It is speculated 
that this could be due to the presence of the salmonellae in phagosomes, unlike 
B.pseudomallei which could be found in the cytoplasm of the host cell. It is possible that 
the conditions in the phagosomes were unsuitable or that the antibiotic simply could not 
penetrate its membrane. 
 Ciprofloxacin was highly bactericidal against Salmonella Typhimurium when the 
bacteria were found in an extracellular environment. Against intracellular salmonellae, 
there was a decrease in activity but the antibiotic remained very effective and 
concentrations of 10xMIC and above showed almost complete clearance of the bacteria 
from the host cells. The MIC value for ciprofloxacin was low (0.125μg/ml) and even with 
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the relatively low peak serum level of 4μg/ml (from a dosage of 400mg), the achievable 
concentration was over 30 times the MIC and in theory, should easily eliminate all the 
S.Typhimurium from the cell. Of course, these results are obtained from an in vitro assay 
using a cell line. Further studies involving animal models need to be carried to verify this.  
 Both chloramphenicol and tetracycline showed similar activity. Both were 
bacteriostatic against extracellular S.Typhimurium at 1xMIC, but bactericidal when 
higher concentrations were used. Both showed a marked decline in activity when used 
against intracellular salmonellae. 
 Rifampicin was also tested against S.Typhimurium. This antibiotic was rapidly 
bactericidal in a dose dependent manner against extracellular salmonellae. The antibiotic 
also performed well against intracellular salmonellae, achieving nearly 80% kill after 6 
hours of incubation. In fact, the antibiotic performed almost as well against intracellular 
bacteria as it did against extracellular bacteria. However, the MIC value for this antibiotic 
is relatively high, at 16μg/ml and coupled with the relatively low peak serum level of 
10μg/ml for an oral dose of 600mg (Vij et al, 1995) suggests that therapeutic applications 
may be limited. However, given the rapid killing and the good rate of cellular 
penetration, rifampicin, if a high enough dosage can be administered, may still be a 
useful fall back drug for use against multi-resistant S.Typhimurium infections. 
 In conclusion, ciprofloxacin and rifampicin showed the best bactericidal activity 
against intracellular S.Typhimurium and would be worth studying further. Most 
antibiotics with the exception of rifampicin exhibited varying levels of decline in 
bactericidal activity when used against intracellular bacteria. Among these, ciprofloxacin 
showed the best cellular penetration.  
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 Our work with antimicrobial drugs combinations revealed that only the 
combination of tetracycline and chloramphenicol showed any synergistic activity 
(although the effect was slight) against S.Typhimurium. In fact, it was found that 
chloramphenicol or tetracycline, when used in combination with ceftriaxone, antagonism 
was observed. β-lactam antibiotics target the penicillin-binding proteins of the bacteria 
and can only act on actively dividing bacteria. Therefore, bacteriostatic drugs often block 
the action of this class of antibiotics.  
 Pre-incubation with interferon-gamma resulted in the activation of the 
antimicrobial responses of the J774.1 cells and this can be observed in the marked 
decrease in bacteria numbers over 6 hours incubation in cells pre-incubated with IFN-γ 
when compared to control cells. In cells pre-incubated with IFN-γ, the number of viable 
bacteria found within the host cells often declined or remained static after infection. In 
the control cells (pre-incubated with 5% BSA, the same diluent used to make up the IFN-
γ), bacterial growth was observed during the same period of incubation.  
 IFN-γ pre-incubated cells infected with S.Typhimurium were then treated with 
various antibiotics in order to determine if the introduction of the antibiotics had any 
additional effect on the killing of the intracellular bacteria. No effect was observed for 
ciprofloxacin, ceftriaxone, rifampicin, cefotaxime, chloramphenicol and tetracycline but 
meropenem was observed to interfere with the killing of intracellular salmonellae by the 
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5.3 Overall Conclusions 
 5.3.1 Intracellular Model of Bacterial Infection 
 Intracellular infection of J774.1 cells by B.pseudomallei and S.Typhimurium has 
been described before (e.g. Foster et al, 2003; Miyagi et al, 1997). Here, we describe for 
the first time the comparative activities of different antibiotics on killing intracellular 
versus extracellular populations, using J774.1 as host cells. Both Burkholderia 
pseudomallei and Salmonella Typhimurium are facultative intracellular pathogens and 
this intracellular milieu is believed to contribute to difficulties in eradicating the bacteria 
using antibiotics, and likely also to aid in the establishment of chronic and latent infective 
states in B.pseudomallei infections. For this study, we had adapted this cell line as a 
possible model for the testing of intracellular activity of antibiotics against these 
organisms. In this model, J774.1 cells were infected with the bacteria and then treated 
with kanamycin or gentamicin. These aminoglycosides had been shown to be rapidly 
bactericidal against exposed bacteria and yet the population of the bacteria sequestered 
within the J774.1 cells were protected from the effect of this antibiotic and in fact, the 
intracellular population can be observed to increase in numbers over time. Therefore, a 
control containing kanamycin (or gentamicin) can be used to estimate the surviving 
intracellular bacterial numbers. Gentamicin has been used before by other works in such 
systems. Its high MIC against B.pseudomallei led us to replace it with kanamycin in this 
model. 
 A model for intracellular B.pseudomallei infection was designed by Inglis et al 
(2000) using Acanthamoeba species as a host organism. However, murine macrophages 
are generally closer to the human macrophages which play host to the B.pseudomallei in 
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human patients. Therefore, we feel that the physiological conditions within the J774.1 
cells may be more comparable to the nature of the human macrophages. 
 J774.1 cells had also been used as hosts for other intracellular pathogens such as 
Listeria monocytogenes (for example, by Chanteux et al in 2003), Legionella 
pneumophila (Higa et al, 1998) and Bartonella henselae (Musso et al, 2001).  
  
5.3.2 Efficacy of Different Antibiotics against Intracellular Bacteria 
 It could be seen from the results above that, while there were some differences in 
the results observed when the same antibiotic was used in the treatment of either 
B.pseudomallei or S.Typhimurium, the antibiotics tested generally showed similar trends 
when used with either target bacterium.  
 Most β-lactam antibiotics showed a decrease in activity when used against 
intracellular bacteria. The decline in activity varied between different members of the 
class, with the cephalosporins ceftazidime, ceftriaxone and cefotaxime showing the 
greatest loss in efficacy. However, while meropenem showed better activity than the 
cephalosporins when used against intracellular B.pseudomallei, the same carbapenem 
showed extremely poor activity against intracellular S.Typhimurium, where almost no 
intracellular killing were observed at all despite the antibiotic being very effective against 
extracellular S.Typhimurium. It is possible that the intracellular salmonellae was found in 
a compartment within the cell into which meropenem could not penetrate or penetrate 
only poorly. This was not observed when meropenem was used against intracellular 
B.pseudomallei perhaps because the bacteria can be found in the cytoplasm of the cell. 
 141
                                             Studies on Antibiotics Action on Intracellular Bacteria 




Piperacillin, alone or in combination with tazobactam, showed good intracellular 
penetration as did amoxicillin-clavulanic acid.  
 Ciprofloxacin, like many fluoroquinolones, showed good activity against 
intracellular bacteria, although it was more effective against intracellular B.pseudomallei. 
This was possibly due to the fact that B.pseudomallei escapes from the phagosome and 
hence could be found in the cytoplasm. The fact that S.Typhimurium can remain within 
the phagosome could be the reason why ciprofloxacin showed a slight loss in efficacy. 
The membrane of the phagosome forms another barrier between the antibiotic and the 
bacteria and though ciprofloxacin was still shown to penetrate the barrier effectively, 
there were some loss in bactericidal activity. 
 The tetracyclines (doxycycline and tetracycline), chloramphenicol and macrolide 
antibiotics are know to be generally bacteriostatic drugs. As expected, these drugs were 
not bactericidal at lower concentrations, although bactericidal activity was observed at 
higher dosage.  
 Rifampicin penetrated into cells very well and it could be observed that 
intracellular killing by rifampicin were almost comparable with the extracellular killing 
of S.Typhimurium and in fact, the intracellular killing by rifampicin surpassed the 
extracellular killing of B.pseudomallei. This supported the observations that rifampicin 
can accumulate within macrophage cells (Najar et al, 1984).  B.pseudomallei had been 
shown to escape from the phagosome (Harley et al, 1998) and therefore exposed to the 
rifampicin in the cytoplasm. The presence of S.Typhimurium in the phagosome may lend it 
some protection. 
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 None of the antibiotics combinations tested showed a strong synergistic action and 
clear antagonism was observed when either of the bacteriostatic drugs chloramphenicol or 
tetracycline was combined with the β-lactam ceftriaxone.   
 Pre-incubation with IFN-γ appeared to activate the native anti-microbial mechanisms 
of the J774.1 cells as reduction in bacterial numbers could be observed after 6 hours of 
incubation. However, no cooperative activity between these mechanisms and antibiotics were 
observed, although meropenem appeared to actually reduce the efficacy of the cell’s 
antibacterial mechanisms. 
 
5.3.3. Future Directions 
 A number of follow up experiments can be conducted to further this project.  
 Firstly, the results for the assays involving B.pseudomallei presented above were only 
preliminary results as the project had to be terminated before more data could be collected. 
Hence, further repeats need to be carried out to ensure that the results obtained are 
completely reproducible and statistically significant. In addition, more data needs to be 
collected for the works involving antibiotics combination and cytokine pre-stimulation in 
order to generate a more accurate statistical model. Interesting antibiotic combinations need 
to be subjected to more vigorous testing using checkerboard titrations involving a wider 
range of concentrations than that tested here in order to improve the accuracy of the 
observations made here.  
 Also, more antibiotics can be tested for their efficacy against intracellular 
B.pseudomallei and S.Typhimurium. This is particularly so in the case of the studies on 
S.Typhimurium, where due to the lack of time, there had been no opportunity to test some of 
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the antibiotics that had been used in the melioidosis study, for example, piperacillin, 
amoxicillin-clavulanic acid and macrolides.  
 Combinations of antibiotics can be tested to determine any interactions, if any. 
Different combinations can have synergistic or antagonistic effects on the action of other 
antibiotics. Due to the highly resistant nature of B.pseudomallei, the use of antibiotic 
combinations may yield a more effective and fast-acting therapy as well as preventing the 
development of resistant strains. Current treatment of melioidosis required prolonged therapy 
with a long period of oral therapy using various combinations of drugs. Finding a more 
effective drug or drug combination could help reduce treatment failures and reduce 
recrudescence. Although S.Typhimurium was less resistant to antibiotics than 
B.pseudomallei, the intracellular lifestyle of this organism meant that many antibiotics would 
have reduced efficacy against the intracellular pathogen when it is sequestered within the 
host cell. Antibiotic combinations, if acting synergistically, may confer a more rapid 
clearance rate and help reduce the risk of inducing resistance as was sometimes the case 
when a drug was prescribed as a monotherapy.  
 Further work can be carried out using J774.1 cells pre-activated with IFN-γ to 
determine if the cellular antimicrobial mechanism can be employed in conjunction with 
antibiotics. It may be possible that the use of certain antibiotics could have a synergistic or 
antagonistic effect. This study had been carried out with J774.1 cells infected by 
S.Typhimurium but only with a limited number of antibiotics. Also, the studies using 
B.pseudomallei had to be terminated before reaching this stage. Other cytokines, particularly 
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) and Tumour Necrosis Factor 
–α (TNF-α) can also be tested for their ability to induce the killing of the intracellular 
bacteria. Optimally, a combination of cytokine therapy and antimicrobial regime could be 
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effective in the clearance of the bacteria and in reducing in the risk of a relapse.  There are a 
few published studies on the combination of stimulatory cytokines and antibiotics on 
clearance of intracellular bacteria by professional phagocytes. Quadrhiri et al (1999) 
combined a number of antibiotics in combination with interferon-γ stimulation against 
intracellular Listeria monocytogenes. It was found that pre-stimulation reduced the sensitivity 
of the intracellular bacteria to ampicillin but it was also observed to increase the effectiveness 
of azithromycin and sparfloxacin. Parallel studies on different classes of microbes have 
shown promise. Clemens et al (2001) showed that IFN-α act synergistically with antifungal 
drugs in the treatment of infections by Cryptococcus neoformans in SCID mice. Such studies 
prompted us to investigate a role for IFN-α in the treatment of melioidosis, as infections 
persisted in many individuals despite prolonged multiple antibiotic therapy. Macrophages are 
known to become chronically infected in these individuals. Salmonellosis can also become 
chronic and recurrent, particularly in AIDS patients, prompting similar studies one 
S.Typhimurium. GM-CSF, another cytokine with the ability to upregulate the killing 
mechanisms of macrophages, has been used successfully as adjunctive therapy with 
antimonial drugs to clear cutaneous leismaniasis in patients refractory to standard therapy 
(Almeida et al, 2005) 
 It was intended to explore the possibility of an intracellular infection model using 
human monocyte-derived macrophages as a host cell. This would be an even more accurate 
in vitro model for the study of B.pseudomallei or S.Typhimurium infection in humans.  In 
this case, it would be advantageous to miniaturise the current assay as attempts to isolate 
human monocytes from whole blood had yielded only small numbers of cells. Alternatively, 
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a human monocyte cell line like Thp-1 could be used although fresh human monocytes would 
be optimal.  
 As the work currently conducted are in vitro studies using cultured cells, the next 
logical phase would be to proceed to an animal model study. The current model does not 
allow prolonged incubation as the cells would begin to die by 24 hours and lose their 
membrane integrity. An animal model would enable a longer-term study involving multiple 
doses of the test antibiotics as would be in the case of a clinical treatment regime. Animal 
models would also provide an environment that is closer to the actual physiological condition 
in the melioidosis patients. However, the cultured cell model presented here allows for rapid 
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Appendix 1: Omitted results 
 These are the results that were not shown in the results and discussion section 
owing to the lack of space. 
 
A1.1: Antibiotics Killing Assay against Burkholderia pseudomallei 
 
 D) Ceftriaxone  
 
Figure A1.1: Graph depicting the activity of ceftriaxone against extracellular 
B.pseudomallei (Time-course showing the bacterial numbers measured over 24hr). 
(MIC=8μg/ml) 
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Figure A1.2: Bar Chart depicting the activity of ceftriaxone against extracellular 
B.pseudomallei (Triplicate results showing the % change in bacterial numbers after 
6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. (MIC=8μg/ml) 
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Figure A1.3: Graph depicting the activity of ceftriaxone against intracellular 
B.pseudomallei within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). (MIC=8μg/ml) 
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Figure A1.4: Bar Chart depicting the activity of ceftriaxone against intracellular 
B.pseudomallei within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. (MIC=8μg/ml) 
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G) Clarithromycin  
Figure A1.5: Graph depicting the activity of clarithromycin against extracellular 
B.pseudomallei (Time-course showing the bacterial numbers measured over 24hr). 
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Figure A1.6: Bar Chart depicting the activity of clarithromycin against extracellular 
B.pseudomallei (Triplicate results showing the % change in bacterial numbers after 
6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 
Figure 5.25 
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Figure A1.7: Graph depicting the activity of clarithromycin against intracellular 
B.pseudomallei within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 
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Figure A1.8: Bar Chart depicting the activity of clarithromycin against intracellular 
B.pseudomallei within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. 
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G) Erythromycin  
 
Figure A1.9: Graph depicting the activity of  erythromycin against extracellular 
B.pseudomallei (Time-course showing the bacterial numbers measured over 24hr). 
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Figure A1.10: Bar Chart depicting the activity of erythromycin against extracellular 
B.pseudomallei (Triplicate results showing the % change in bacterial numbers after 
6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 
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Figure A1.11: Graph depicting the activity of erythromycin against intracellular 
B.pseudomallei within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 
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Figure A1.12: Bar Chart depicting the activity of erythromycin against intracellular 
B.pseudomallei within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. 

























Kanamycin 100µg/ml Erithromycin 128 µg/ml 1xMIC











                                             Studies on Antibiotics Action on Intracellular Bacteria 
                                             Appendix 1.1 –Data Excluded From Thesis Main Body  




J) Tetracycline  
Figure A1.13: Graph depicting the activity of tetracycline against extracellular 
B.pseudomallei (Time-course showing the bacterial numbers measured over 24hr). 
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Figure A1.14: Bar Chart depicting the activity of tetracycline against extracellular 
B.pseudomallei (Triplicate results showing the % change in bacterial numbers after 
6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 
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Figure A1.15: Graph depicting the activity of tetracycline against intracellular 
B.pseudomallei within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 
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Figure A1.16: Bar Chart depicting the activity of tetracycline against intracellular 
B.pseudomallei within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. 
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K) Rifampicin  
 
Figure A1.17: Graph depicting the activity of rifampicin against extracellular 
B.pseudomallei (Time-course showing the bacterial numbers measured over 24hr). 
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Figure A1.18: Bar Chart depicting the activity of rifampicin against extracellular 
B.pseudomallei (Triplicate results showing the % change in bacterial numbers after 
6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 
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Figure A1.19: Graph depicting the activity of rifampicin against intracellular 
B.pseudomallei within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 
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Figure A1.20: Bar Chart depicting the activity of rifampicin against intracellular 
B.pseudomallei within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. 
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A1.2: Antibiotics Killing Assay against Salmonella Typhimurium 
 
B) Cefotaxime  
 
Figure A1.21: Graph depicting the activity of cefotaxime against extracellular 
S.Typhimurium (Time-course showing the bacterial numbers measured over 24hr). 
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Figure A1.22: Bar Chart depicting the activity of cefotaxime against extracellular 
S.Typhimurium (Triplicate results showing the % change in bacterial numbers 
after 6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 
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Figure A1.23: Graph depicting the activity of cefotaxime against intracellular 
S.Typhimurium within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 
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Figure A1.24: Bar Chart depicting the activity of cefotaxime against intracellular 
S.Typhimurium within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. 
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D) Chloramphenicol  
 
Figure A1.25: Graph depicting the activity of chloramphenicol against extracellular 
S.Typhimurium (Time-course showing the bacterial numbers measured over 24hr). 
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Figure A1.26: Bar Chart depicting the activity of chloramphenicol against 
extracellular S.Typhimurium (Triplicate results showing the % change in bacterial 
numbers after 6hr of incubation). The error bars show the standard deviation 
between the readings obtained for each set of the triplicate. 
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Figure A1.27: Graph depicting the activity of chloramphenicol against intracellular 
S.Typhimurium within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 
Chloramphenicol Killing Assay vs Intracellular 
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Figure A1.28: Bar Chart depicting the activity of chloramphenicol against 
intracellular S.Typhimurium within J774.1 cells (Triplicate results showing the % 
change in bacterial numbers after 6hr of incubation). The error bars show the 
standard deviation between the readings obtained for each set of the triplicate. 
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 G) Tetracycline  
Figure A1.29: Graph depicting the activity of tetracycline against extracellular 
S.Typhimurium (Time-course showing the bacterial numbers measured over 24hr). 
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Figure A1.30: Bar Chart depicting the activity of tetracycline against extracellular 
S.Typhimurium (Triplicate results showing the % change in bacterial numbers 
after 6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 
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Figure A1.31: Graph depicting the activity of tetracycline against intracellular 
S.Typhimurium within J774.1 cells (Time-course showing the bacterial numbers 
measured over 24hr). 
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Figure A1.32: Bar Chart depicting the activity of tetracycline against intracellular 
S.Typhimurium within J774.1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate. 
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A1.3: Effect of Antibiotics on S.Typhimurium within THP-1 Human Monocyte-like  




Figure A1.33: Bar Chart depicting the activity of cefotaxime against intracellular 
S.Typhimurium within THP-1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate 
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Figure A1.34: Bar Chart depicting the activity of ceftriaxone against intracellular 
S.Typhimurium within Thp-1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate 





























Gentamicin 100µg/ml Ceftriaxone 1xMIC (0.5µg/ml) Ceftriaxone 10xMIC (5µg/ml)







                                             Studies on Antibiotics Action on Intracellular Bacteria 
                                             Appendix 1.3 –Data Excluded From Thesis Main Body  






Figure A1.35: Bar Chart depicting the activity of ciprofloxacin against intracellular 
S.Typhimurium within THP-1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate 






























Gentamicin 100µg/ml Ciprofloxacin 1xMIC (0.125µg/ml)
Ciprofloxacin 10xMIC (1.25µg/ml) Ciprofloxacin 20xMIC (2.5µg/ml)
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Figure A1.36: Bar Chart depicting the activity of chloramphenicol against 
intracellular S.Typhimurium within THP-1 cells (Triplicate results showing the % 
change in bacterial numbers after 6hr of incubation). The error bars show the 
standard deviation between the readings obtained for each set of the triplicate 



























Gentamicin 100µg/ml Chloramphenicol 1xMIC (16µg/ml)
Chloramphenicol 10xMIC (160µg/ml) Chloramphenicol 20xMIC (320µg/ml)
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Figure A1.37: Bar Chart depicting the activity of meropenem against intracellular 
S.Typhimurium within THP-1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate 


























Gentamicin 100µg/ml Meropenem 1xMIC (0.5µg/ml) Meropenem 10xMIC (5µg/ml)
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 F) Rifampicin 
 
 
Figure A1.38: Bar Chart depicting the activity of rifampicin against intracellular 
S.Typhimurium within THP-1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate 
























Gentamicin 100µg/ml Rifampicin 1xMIC (16µg/ml) Rifampicin 10xMIC (160µg/ml)
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Figure A1.39: Bar Chart depicting the activity of tetracycline against intracellular 
S.Typhimurium within THP-1 cells (Triplicate results showing the % change in 
bacterial numbers after 6hr of incubation). The error bars show the standard 
deviation between the readings obtained for each set of the triplicate 




























Gentamicin 100µg/ml Tetracycline 1xMIC (8µg/ml) Tetracycline 10xMIC (80µg/ml)
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A1.4: Antibiotics Combinations against Salmonella Typhimurium 
 
  
Table A1.1: Table listing the results from antibiotic combinations tested against 
extracellular Salmonella Typhimurium. For ease of comparison, the % change in 
bacteria after 6 hours from the 3 sets of assays were averaged and shown below. 
Antibiotics Combination Average % change in cell numbers after 6 hours 
Cip 1 Chl 1 Cip1xChl1 
-99.99 +8.62 -76.29 
Cip1 Chl10 Cip1xChl10 
Ciprofloxacin + 
Chloramphenicol 
-99.99 -85.81 -97.05 
Cip1 Cro1 Cip1xCro1 Ciprofloxacin + 
Ceftriaxone -99.99 -99.95 -99.99 
Cip1 Rif1 Cip1xRif1 Ciprofloxacin + Rifampicin 
-99.99 -97.59 -98.75 
Rif1 Chl1 Rif1xChl1 
-97.59 +8.62 -93.32 
Rif1 Chl10 Rif1xChl10 
Rifampicin + 
Chloramphenicol  
-97.59 -85.81 -99.44 
Rif1 Cro1 Rif1xCro1 Rifampicin + Ceftriaxone 
-99.92 -99.51 -99.68 
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Table A1.1 (continued): Table listing the results from antibiotic combinations tested 
against extracellular Salmonella Typhimurium 
Antibiotics Combination 
(continued) 
Average % change in cell numbers after 6 hours 
Cro1 Chl1 Cro1xChl1 
-99.95 +8.62 -25.47 
Cro1 Chl10 Cro1xChl10 
Ceftriaxone + 
Chloramphenicol 
-99.95 -85.81 -96.37 
 
Tet1 Cip1 Tet1xCip1 
-3.79 -99.98 -92.29 
Tet10 Cip1 Tet10xCip1 
Tetracycline + 
Ciprofloxacin 
-74.17 -99.98 -91.90 
Tet1 Cro1 Tet1xCro1 
+8.05 -99.91 -63.74 
Tet10 Cro1 Tet10xCro1 
Tetracycline + Ceftriaxone 
-27.72 -99.91 -84.78 
Tet1 Rif1 Tet1xRif1 
+6.85 -96.94 -84.57 
Tet10 Rif1 Tet10xRif1 
Tetracycline + Rifampicin 
-40.35 -96.94 -93.20 
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Table A1.1 (continued): Table listing the results from antibiotic combinations tested 
against extracellular Salmonella Typhimurium 
Antibiotics Combination 
(continued) 
Average % change in cell numbers after 6 hours 
Tet1 Chl1 Tet1xChl1 
-4.03 -17.19 -34.81 
Tet1 Chl10 Tet1xChl10 
-4.03 -89.58 -93.95 
Tet10 Chl1 Tet10xChl1 
-65.21 -17.19 -91.53 
Tet10 Chl10 Tet10xChl10 
Tetracycline + 
Chloramphenicol 
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Table A1.2: Table listing the results from antibiotic combinations tested against 
intracellular Salmonella Typhimurium. The results in graphical form can be viewed 
in Appendix 1 (A1.4). For ease of comparison, the % change in bacteria after 6 
hours from the 3 sets of results were averaged and shown below.  
Antibiotics Combination Average % change in bacteria numbers after 6 hours 
Cip 1 Chl 1 Cip1xChl1 
-87.13 -20.41 -80.72 
Cip1 Chl10 Cip1xChl10 
-87.13 -67.64 -91.73 
Cip10 Chl1 Cip10xChl1 
-99.31 -20.41 -96.71 
Cip10 Chl10 Cip10xChl10 
Ciprofloxacin + 
Chloramphenicol 
-99.31 -67.64 -97.29 
Cip1 Cro1 Cip1xCro1 Ciprofloxacin + 
Ceftriaxone -80.59 -2.94 -72.22 
Cip1 Rif1 Cip1xRif1 Ciprofloxacin + Rifampicin 
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Table A1.2 (continued): Table listing the results from antibiotic combinations tested 
against intracellular Salmonella Typhimurium 
Antibiotics Combination Average % change in bacteria numbers after 6 hours 
Rif1 Chl1 Rif1xChl1 
-89.24 -38.66 -99.51 
Rif1 Chl10 Rif1xChl10 
-89.24 -83.07 -99.65 
Rif10 Chl1 Rif10xChl10 
-99.95 -38.66 -99.95 
Rif10 Chl10 Rif10xChl10 
Rifampicin + 
Chloramphenicol  
-99.95 -83.07 -99.95 
Rif1 Cro1 Rif1xCro1 Rifampicin + Ceftriaxone 
-89.24 +1.85 -87.38 
Cro1 Chl1 Cro1xChl1 
-3.95 -58.59 -59.23 
Cro1 Chl10 Cro1xChl10 
-3.95 -87.71 -70.07 
Cro10 Chl1 Cro10xChl1 
-82.33 -58.59 -85.48 
Cro10 Chl10 Cr10xChl10 
Ceftriaxone + 
Chloramphenicol 
-82.33 -87.71 -89.72 
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Table A1.2 (continued): Table listing the results from antibiotic combinations tested 
against intracellular Salmonella Typhimurium 
Antibiotics Combination Average % change in bacteria numbers after 6 hours 
Tet1 Cip1 Tet1xCip1 
+35.14 -69.26 -50.71 
 
Tet1 Cip10 Tet1xCip10 
+35.14 -98.61 -95.57 
Tet10 Cip1 Tet10xCip1 
-17.58 -69.26 -49.88 
Tet10 Cip10 Tet10xCip10 
Tetracycline + 
Ciprofloxacin 
-17.58 -98.61 -91.93 
Tet1 Cro1 Tet1xCro1 
+23.65 +6.80 +20.59 
Tet1 Cro10 Tet1xCro10 
+23.65 -55.72 -7.18 
Tet10 Cro1 Tet10xCro1 
-20.88 +6.80 -29.42 
Tet10 Cro10 Tet10xCro10 
Tetracycline + Ceftriaxone 
-20.88 -55.72 -38.35 
 
 206
                                             Studies on Antibiotics Action on Intracellular Bacteria 
                                             Appendix 1.4 –Data Excluded From Thesis Main Body  




Table A1.2 (continued): Table listing the results from antibiotic combinations tested 
against intracellular Salmonella Typhimurium 
Antibiotics Combination Average % change in bacteria numbers after 6 hours 
Tet1 Rif1 Tet1xRif1 
+50.88 -92.76 -93.35 
Tet1 Rif10 Tet1xRif10 
+50.88 -98.85 -98.50 
Tet10 Rif1 Tet10xRif1 
+0.28 -92.76 -97.21 
 
Tet10 Rif10 Tet10xRif0 
Tetracycline + Rifampicin 
+0.28 -98.85 -98.85 
Tet1 Chl1 Tet1xChl1 
+5.34 -14.93 -22.64 
Tet1 Chl10 Tet1xChl10 
+5.34 -84.07 -92.82 
Tet10 Chl1 Tet10xChl1 
-30.83 -14.93 -44.21 
Tet10 Chl10 Tet10xChl10 
Tetracycline + 
Chloramphenicol 




                                             Studies on Antibiotics Action on Intracellular Bacteria 
                                             Appendix 1.5 –Data Excluded From Thesis Main Body  




A1.5 The Effect of Interferon-γ used in tandem with antibiotics on the survival of 
intracellular S.Typhimurium 
 
A) Cefotaxime and IFN-γ 
 
Figure A1.60: Bar Chart depicting the effect of pre-incubation with interferon-
gamma one the activity of cefotaxime against intracellular Salmonella Typhimurium 
(Triplicate results showing the % change in bacterial numbers after 6hr of 
incubation). The error bars show the standard deviation between the readings 
obtained for each set of the triplicate. 
Effect of Interferon on efficacy of Cefotaxime vs intracellular S .Typhimurium in J


























Control (with BSA only) + Gentamicin 100µg/ml Control (with BSA only) + Cefotaxime 10xMIC
Interferon 100 units/ml + Gentamicin 100µg/ml Interferon 100 units/ml + Cefotaxime 10xMIC
Effect of Interferon-γ on the Efficacy of Cefotaxime vs Intracellular 
S.Typhimurium in J774.1 
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B) Ceftriaxone and IFN-γ 
 
Figure A1.61: Bar Chart depicting the effect of pre-incubation with interferon-
gamma one the activity of ceftriaxone against intracellular Salmonella 
Typhimurium (Triplicate results showing the % change in bacterial numbers after 
6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 
Effect of Interferon on efficacy of Ceftriaxone vs intracellular S .Typhimurium in 
J774.1

























Control (with BSA only) + Gentamicin 100µg/ml Control (with BSA only) + Ceftriaxone 10xMIC
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 C) Chloramphenicol and IFN-γ 
 
Figure A1.62: Bar Chart depicting the effect of pre-incubation with interferon-
gamma one the activity of chloramphenicol against intracellular Salmonella 
Typhimurium (Triplicate results showing the % change in bacterial numbers after 
6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 
Effect of Interferon on the Efficacy of Chloramphenicol vs Intracellular 
S .Typhimurium in J774.1



























Control (with BSA only) + Gentamicin 100µg/ml Control (with BSA only) + Chloramphenicol 10xMIC
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 D) Ciprofloxacin with IFN-γ 
 
Figure A1.63: Bar Chart depicting the effect of pre-incubation with interferon-
gamma one the activity of ciprofloxacin against intracellular Salmonella 
Typhimurium (Triplicate results showing the % change in bacterial numbers after 
6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 
Effect of Interferon on efficacy of Ciprofloxacin vs intracellular 
S .Typhimurium in J774.1























Control (with BSA only) + Gentamicin 100μg/ml Control (with BSA only) + Ciprofloxacin 1xMIC
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 E) Meropenem and IFN-γ 
 
Figure A1.64: Bar Chart depicting the effect of pre-incubation with interferon-
gamma one the activity of meropenem against intracellular Salmonella 
Typhimurium (Triplicate results showing the % change in bacterial numbers after 
6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 
Effect of Interferon on the Efficacy of Meropenem vs Intracellular 
S .Typhimurium in J774.1























Control (with BSA only) + Gentamicin 100μg/ml Control (with BSA only) + Meropenem 10xMIC
Interferon 100 units/ml + Gentamicin 100μg/ml Interferon 100 units/ml + Meropenem 10xMIC  
 
The pre-incubation of J774.1 cells with IFN-γ appeared to reduce the bacterial 
growth compared to that observed when untreated cells were infected and treated with 
meropenem. However, it was also clear that the cells pre-incubated with IFN-γ and then  
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infected and treated with meropenem still showed bacterial growth while the cells treated 
with IFN-γ but without meropenem actually showed a decline in bacterial numbers. This 
could suggest that meropenem had an antagonistic effect on the anti-bacterial action 
mediated by IFN-γ. 
 
F) Rifampicin and IFN-γ 
 
Figure A1.65: Bar Chart depicting the effect of pre-incubation with interferon-
gamma one the activity of rifampicin against intracellular Salmonella Typhimurium 
(Triplicate results showing the % change in bacterial numbers after 6hr of 
incubation). The error bars show the standard deviation between the readings 
obtained for each set of the triplicate. 
Effect of Interferon on the Efficacy of Rifampicin vs Intracellular 
S .Typhimurium in J774.1

























Control (with BSA only) + Gentamicin 100µg/ml Control (with BSA only) + Rifampicin 1xMIC 
Interferon 100 units/ml + Gentamicin 100µg/ml Interferon 100 units/ml + Rifampicin 1xMIC  
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  G)  Tetracycline and IFN-γ 
 
Figure A1.66: Bar Chart depicting the effect of pre-incubation with interferon-
gamma one the activity of tetracycline against intracellular Salmonella 
Typhimurium (Triplicate results showing the % change in bacterial numbers after 
6hr of incubation). The error bars show the standard deviation between the 
readings obtained for each set of the triplicate. 































% change in number of bacteria
Control (with BSA only) + Gentamicin 100µg/ml Control (with BSA only) + Tetracycline 10xMIC 
Interferon 100 units/ml Gentamicin 100µg/ml Interferon 100 units/ml + Tetracycline 10xMIC 
Effect of Interferon-γ on the Efficacy of Tetracycline vs Intracellular 
S.Typhimurium in J774.1 
(% change in number of bacteria after 6hr) 
 
 There was little difference in respect of the efficacy of tetracycline between the 
cells pre-incubated with IFN-γ and cells that were not. The difference observed in the 




                                             Studies on Antibiotics Action on Intracellular Bacteria 




Appendix 2: Additional Results 
 
 An additional set of results is shown below to demonstrate that the results shown 
in the earlier sections were reproducible. Due to the premature termination of the project 
involving B.pseudomallei, attempts to repeat all the work done were not completed and 
hence not presented. The experiments involving Salmonella Typhimurium were 
conducted thrice and one set of these additional results obtained is presented below. 
 
A 2.1: Antibiotic Killing Assay 
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Ceftriaxone  1xMIC (0.5 µg/ml) Ceftriaxone  10xMIC (5 µg/ml)
Ceftriaxone  50xMIC (25 µg/ml) Ceftriaxone  100xMIC 50 µg/ml)  



























Gentamycin 100 µg/ml Ceftriaxone  1xMIC (0.5 µg/ml) Ceftriaxone  10xMIC (5 µg/ml)
Ceftriaxone  50xMIC (25 µg/ml) Ceftriaxone  100xMIC (50 µg/ml)
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 B) Cefotaxime 























Cefotaxime  1xMIC (0.25 µg/ml) Cefotaxime  10xMIC (2.5 µg/ml) Cefotaxime  50xMIC (12.5 µg/ml)
Cefotaxime  100xMIC (25 µg/ml) Cefotaxime  400xMIC (100 µg/ml)  





























Gentamycin 100 µg/ml Cefotaxime  1xMIC (0.25 µg/ml)
Cefotaxime  10xMIC (2.5 µg/ml) Cefotaxime  50xMIC (12.5 µg/ml)
Cefotaxime  100xMIC (25 µg/ml) Cefotaxime  400xMIC (100 µg/ml)  
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 C) Ciprofloxacin 























Ciprofloxacin  1xMIC (0.125 µg/ml) Ciprofloxacin  10xMIC (1.25 µg/ml)
Ciprofloxacin  20xMIC (2.5 µg/ml) Ciprofloxacin  50xMIC (6.25 µg/ml)  



























Gentamycin 100 µg/ml Ciprofloxacin  1xMIC (0.125 µg/ml)
Ciprofloxacin  10xMIC (1.25 µg/ml) Ciprofloxacin  20xMIC (2.5 µg/ml)
Ciprofloxacin  50xMIC (6.25 µg/ml)  
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 D) Chloramphenicol 























Chloramphenicol  1xMIC (16 µg/ml) Chloramphenicol  10xMIC (160 µg/ml)
Chloramphenicol  20xMIC (320 µg/ml) Chloramphenicol  30xMIC (480 µg/ml)  



























Gentamycin 100 µg/ml Chloramphenicol  1xMIC (16 µg/ml)
Chloramphenicol  10xMIC (160 µg/ml) Chloramphenicol  20xMIC (320 µg/ml)
Chloramphenicol  30xMIC (480 µg/ml)  
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 E) Meropenem 























Meropenem  1xMIC (0.5 µg/ml) Meropenem  10xMIC (5 µg/ml)
Meropenem  50xMIC (25 µg/ml) Meropenem  100xMIC (50 µg/ml)  

























Gentamycin 100 µg/ml Meropenem  1xMIC (0.5 µg/ml) Meropenem  10xMIC (5 µg/ml)
Meropenem  50xMIC (25 µg/ml) Meropenem  100xMIC (5µg/ml)  
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 F) Rifampicin 























Rifampicin  1xMIC (16 µg/ml) Rifampicin  10xMIC (160 µg/ml)
Rifampicin  20xMIC (320 µg/ml) Rifampicin  30xMIC (480 µg/ml)  


























Gentamycin 100 µg/ml Rifampicin  1xMIC (16 µg/ml) Rifampicin  10xMIC (160 µg/ml)
Rifampicin  20xMIC (320 µg/ml) Rifampicin  30xMIC (480 µg/ml)  
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 G) Tetracycline 
























Tetracycline  1xMIC (8 µg/ml) Tetracycline  10xMIC (80 µg/ml)
Tetracycline  20xMIC (160 µg/ml) Tetracycline  50xMIC (400 µg/ml)  
























Gentamycin 100 µg/ml Tetracycline  1xMIC (8 µg/ml)
Tetracycline  10xMIC (80 µg/ml) Tetracycline  20xMIC (160 µg/ml)
Tetracycline  30xMIC (400 µg/ml)  
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A2.2: Interferon-gamma and antibiotics 
 
A) IFN+Cefotaxime 
Effect of Interferon on the Efficacy of Cefotaxime vs Intracellular 
S .Typhimurium in J774.1























Control (with BSA only) + Gentamicin 100μg/ml Control (with BSA only) + Cefotaxime 10xMIC 
Interferon 100 units/ml + Gentamicin 100μg/ml Interferon 100 units/ml + Cefotaxime 10xMIC 
 
B) IFN+Ceftriaxone 
Effect of Interferon on the Efficacy of Ceftriaxone vs Intracellular 
S .Typhimurium in J774.1



























Control (with BSA only) + Gentamicin 100μg/ml Control (with BSA only) + Ceftriaxone 1xMIC
Interferon 100 units/ml + Gentamicin 100μg/ml Interferon 100 units/ml + Ceftriaxone 1xMIC  
 223
                                             Studies on Antibiotics Action on Intracellular Bacteria 





Effect of Interferon on the Efficacy of Chloramphenicol vs Intracellular 
S.Typhimurium in J774.1

























Control (with BSA only) + Gentamicin 100µg/ml Control (with BSA only) + Chloramphenicol 10xMIC 
Interferon 100 units/ml Gentamicin 100µg/ml Interferon 100 units/ml + Chloramphenicol 10xMIC  
D) IFN+Ciprofloxacin 
Effect of Interferon on the Efficacy of Ciprofloxacin vs Intracellular 
S .Typhimurium in J774.1

























Control (with BSA only) + Gentamicin 100μg/ml Control (with BSA only) + Ciprofloxacin 1xMIC
Interferon 100 units/ml + Gentamicin 100μg/ml Interferon 100 units/ml + Ciprofloxacin 1xMIC  
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Effect of Interferon on the Efficacy of Meropenem vs Intracellular 
S .Typhimurium in J774.1























Control (with BSA only) + Gentamicin 100μg/ml Control (with BSA only) + Meropenem 10xMIC
Interferon 100 units/ml + Gentamicin 100μg/ml Interferon 100 units/ml + Meropenem 10xMIC  
 
F) IFN+Rifampicin 
Effect of Interferon on the Efficacy of Rifampicin vs Intracellular 
S .Typhimurium in J774.1

























Control (with BSA only) + Gentamicin 100µg/ml Control (with BSA only) + Rifampicin 1xMIC 
Interferon 100 units/ml Gentamicin 100µg/ml Interferon 100 units/ml + Rifampicin 1xMIC  
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Effect of Interferon on the Efficacy of Tetracycline vs Intracellular 
S .Typhimurium in J774.1

























Control (with BSA only) + Gentamicin 100µg/ml Control (with BSA only) + Tetracycline 10xMIC 
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Appendix 3: Materials 
 
A3.1: Antibiotics 
 1) Amoxycillin-clavulanic acid (Augmentin) 
  (Beecham (Glaxo SmithKline), 7783001.6) 
 2) Cefotaxime, sodium  (Sigma-Aldrich, C-7912) 
 3) Ceftazidime (Fortum®) (Glaxowellcome) 
 3) Ceftriaxone, sodium  (Sigma-Aldrich, C-5793) 
 4) Chloramphenicol (Sigma-Aldrich, C-0378) 
 5) Ciprofloxacin (Ciprobay 100®) (Bayer, CAN2B) 
 6) Clarithromycin (Klacid®IV) (Abbott, G656) 
 7) Doxycycline, hydrochloride (Sigma-Aldrich, D-9891) 
 8) Erythromycin (Sigma-Aldrich, E-5389) 
 9) Gentamicin, sulphate (Sigma-Aldrich, G-1264) 
 10) Kanamycin, monosulphate (Sigma-Aldrich, K-1377) 
 11) Meropenem (Meronem®) (Zeneca) 
 12) Piperacillin, sodium (Pipracil®) (Lederle, 3880-18) 
 13) Piperacillin-Tazobactam (Tazocin®) 
  (Lederle, NDC 0206-9455-11) 
 14) Rifampicin (Sigma-Aldrich, R-3501) 
 15) Tetracycline, HCL (Sigma-Aldrich, T-3383) 
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A3.2: Other Materials 
 1) Brain Heart Infusion Broth (BBL, BBL211059) 
 2) Dulbecco’s Modified Eagle’s Medium (JRH Biosciences, J1441-500M) 
  - 4500mg/L Glucose 
  - 4mM L-Glutamine 
  - Pyridoxine HCL 
  - Without Sodium Pyruvate 
 3) Fetal Bovine Serum (Hyclone) 
 4) L-Glutamine (Sigma-Aldrich, G-3126) 
 5) Hepes Buffer (Sigma-Aldrich, H-0887) 
 6) Interferon-γ (Mouse) (Sigma-Aldrich, I-4777) 
 7) L-15 Medium Leibovitz (Sigma-Aldrich, L-5520) 
 8) Mueller-Hinton Broth (Difco, 99-075717)  
 9) Nutrient Agar (Oxoid, CM3) 
 10) Phosphate Buffered Saline (PBS) (Oxoid, BR0014G) 
 11) Acridine Orange (Sigma-Aldrich, A-4921) 
 12) Crystal Violet (Merck, 1407)  
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